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Summary 
Oxidative stress may be connected to cancer. The present work has addressed several 
biomarkers of oxidative stress and antioxidant status in a group of prostate cancer 
(PC) patients compared to a group of healthy men. Results indicate higher oxidative 
stress among the PC patients than the reference population. 
Epidemiological studies have suggested that dietary factors modulate risk of PC. 
Administration of dietary compounds, with minimal side effects, to prevent, slow or 
reverse PC, could be attractive as an addition to conventional PC treatment. 
The current work presents interim results (27 patients of 102) of a clinical study 
investigating whether diagnosed, localised PC may benefit from a food intervention. 
The study is the “Prostate cancer, phytochemical and PUFA intervention study” 
(PFPI). PC patients were randomized in tomato, multidiet and control groups. The 
tomato group patients received 200 – 250 grams tomato products daily, while the 
multidiet group participants were given pomegranate and grape juices, green and 
black tea, selenium, omega-3 and soy in addition to the same amount of tomatoes as 
the tomato group, for a period of three weeks. Prostate specific antigene (PSA) and 
biomarkers of oxidative stress were determined in blood and urine before and after 
the intervention. 
The intervention compliance was excellent. Biomarkers of oxidative stress 
determined in plasma and urine before and after the intervention, revealed no effects 
on oxidative stress. The tomato group experienced a non-significant trend of PSA 
reduction compared to the control group (p=0.072). The multidiet group showed a 
slightly weaker trend of reduction (p=0.114), while statistically significant PSA 
reduction (p=0.045) was detected over the three weeks’ intervention when comparing 
the intervention groups to the control group. 
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1. Introduction and background 
1.1 Prostate cancer 
1.1.1 Epidemiology, incidence, mortality and trends 
Prostate cancer (PC) is the most common cancer among Norwegian men (1). The 
Norwegian rate of mortality from PC is among the highest in the world. In 2004 there 
were 1074 deaths while in 2006 1042 Norwegian men died from PC. There is some 
evidence that recent age-adjusted mortality trends are plateauing or beginning to 
decline (2). Internationally, PC is the second highest cancer related death cause in 
men in the western countries (3).  
Due to the ageing male population, the disease is estimated to increase by 40% 
towards 2020. In the absence of competing causes of death, approximately one in 
eight men currently develop PC in their lifetime (defined as ages 0-74) (2). 
PC incidence and mortality rates are much lower in Japan (8 deaths per 100000 in 
2002) and other Asian countries than in Western countries (32 deaths per 100000 in 
2002 in Norway) (4). However, focal non–invasive PC has been shown to be as 
common in Japan as in the Western countries, and migration from Japan to California 
shows 4-fold increase in risk of clinically diagnosed PC (5). This indicates that 
lifestyle and especially diet influence the development of aggressive disease. 
Recently, a rising trend in incidence and mortality has been seen in Asia. Adaptation 
of Western lifestyle and diet may explain this development (6). 
Due to the availability of prostate specific antigen (PSA) measurement there was a 
considerable increase in age-adjusted incidence of PC from 1988 to 1992, in 
symptomatic and asymptomatic PC. In Norway PSA testing was available from 1989 
(7), but systematic screening has not been introduced to date. In 2007 4391 new cases 
of PC were diagnosed in Norway, an increase of 15% from 2006. The increase is 
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explained by PSA testing. PC screening by use of PSA is controversial because it 
detects small cancers (0.4 mL) which are clinically insignificant in otherwise healthy 
non-symptomatically men. The effect of PSA screening on PC mortality is not clear 
(8).  
1.1.2 Risk according to age, race and family 
Age is the most profound risk factor of all cancers, and this is also true for PC. 
Seventy percent of men above eighty years have asymptomatic PC, and are likely to 
die with it rather than from it. Men of African etnicity have higher risk of developing 
PC than men of other races (9). 
Family history, including first degree relatives with PC has been recognised as a risk 
factor, especially for those who are diagnosed with PC before 60 years of age. 
Genetic factors have been saught, but no strong single gene mutations like BRCA in 
breast cancer have been found. However, polymorphisms in the Ribonuclease L 
(RNASEL) (also known as hereditary PC 1, HPC1) gene have been connected to 
hereditary PC and to disease severity. Other PC susceptibility genes have been 
identified and the functions of the gene products are related to inflammation and 
oxidative stress (9). Recently, a Swedish research team documented a cumulative 
effect of five different SNPs (single nucleotide polymorphisms) on risk of PC, and 
this result has been confirmed in other populations (10). 
1.1.3 Alcohol, tobacco, overweight and inflammation 
Intake of alcoholic beverages is not proven to influence on the risk of PC. Tobacco 
use is not an established cause of PC (11), but  there are indications of a worse 
prognosis for smokers with PC (12). 
Obesity, diabetes type 2 and metabolic syndrome increase worldwide. Low grade 
inflammation, oxidative stress and hormonal changes accompany these conditions, 
and these are factors that may influence on the pathogenesis of PC. Obesity in early 
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life ( < 30 yrs) seems to have a strong inverse association with PC risk in middle or 
old age (13).  There are some indications that diabetes protect against low-grade PC, 
while obesity seems to increase the risk of aggressive disease (13;14). Obesity is 
associated with increased levels of Insulin-like growth factor 1 (IGF-1), and elevated 
IGF-1 may increase the risk of PC. IGF-1 is a growth factor associated with 
inflammation. Chronic low grade inflammation may be a consequence of obesity, and 
has been associated with enhanced tumor growth. However, how the epidemic of 
obesity influences the risk of PC needs to be investigated further (15). 
Chronic inflammation is one probable factor in the development of PC. Chronic 
inflammation may lead to cell death. Furthermore, accumulation of inflammatory 
cells and release of pro-inflammatory mediators including cytokines, chemokines, 
prostaglandines and reactive oxygen species (ROS) are related to cancer development 
(16). In addition to stimulating the inflammation, many of these mediators may 
stimulate cell growth, angiogenesis and mutations. The cytokine production is often 
disturbed or changed in malign conditions and this imbalance may induce disease 
progression (17). 
Assessing biomarkers of inflammation in relation to PC, such as C-reactive protein 
(CRP), interleukin-8 (IL-8) and tumor necrosis factor alpha (TNF alpha) would be of 
great interest, but it is beyond the scope of this master thesis. 
1.1.4 Physical activity 
Proposed mechanisms regarding physical activity and its possible effect on PC are 
modulation of hormone levels, obesity prevention, enhanced immune function and 
oxidative stress reduction. Physical activity may increase the production of sex 
hormone-binding globulin, resulting in lower levels of free testosterone (18). When 
androgen levels are severely depressed, as in castration, PC is not observed. Athletes 
have been shown to have lowered levels of testosterone (19). Most likely, exercise 
has an indirect effect on PC risk by preventing obesity. The evidence for the 
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association between physical activity and PC risk is however inconsistent and too 
week to draw conclusions (11). 
Most research has focused on physical activity in cancer prevention, but exercise 
could be of importance in detection, quality of life, rehabilitation and survival after 
diagnosis (18). 
1.1.5 The prostate gland 
The walnut sized prostate gland is a part of the male reproductive system and lies just 
below the urine bladder (Figure 1.1). The urethra and the seminal ducts fuse while 
passing through the gland. The prostate produces an alkaline liquid which constitutes 
10-30% of the seminal fluid. During ejaculation, both smooth muscle in the gland and 
muscles of the pelvic floor contract to expel semen. Benign prostate hyperplasia is a 
condition in elderly men where enlargement of the prostate may affect urination.  
 
Figure 1.1 The prostate gland and male abdomen (20) 
Free testosterone is reduced to 5-alpha-dihydrotestosterone (DHT) in the prostate 
tissue by the cytoplasmic enzyme 5-alpha reductase. The growth of prostate is 
regulated by testosterone and the more potent DHT. High levels of male sex 
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hormones in plasma are known to increase the risk of PC. But from recent findings, 
DHT level within the prostate gland seems to be of greater importance (21). 
The 5-alpha reductase inhibitors are drugs that block the convertion of testosterone to 
DHT. Results from the Prostate Cancer Prevention Trial suggest that Finasteride, a 5-
alpha reductase inhibitor is capable of slowing the development of early PC. Reduce, 
a study examining effects of the more effective 5-alpha reductase inhibitor 
Dutasteride, will terminate this year and it is expected that the results from this study 
may change the current practice of early PC treatment (22). 
1.1.6 PC pathology 
PC is a heterogeneous disease with multiple causes and variable progression. It takes 
10 – 30 years to develop, and the sequence of events is only partly understood. 
Cancer is often divided into four stages: initiation, clonal expansion, progression and 
metastasising.  
Cancer may be initiated by unrepaired damage to deoxyribonucleic acids (DNA) that 
switch on a proto-oncogene or switch off a tumor suppressor gene. Damaging 
mutations to genes that control the cell cycle, growth, apoptosis and survival make 
the cell able to divide with a damaged DNA and the cell is more likely to acquire 
more mutations. 
Mutations to receptors of paracrine signaling molecules increase the independence of 
the transformed cells. Mutated cells will divide faster than their healthy neighbors, 
resulting in a clonal expansion. 
The progression of PC may be ongoing for many years from the initiation until the 
tumor is recognized by the host. The neoplastic cells grow in number and size, and 
mutations accumulate. Factors that increase cell proliferation, decrease cell apoptosis 
and stimulate to cell growth are factors that may aggravate and accelerate the 
development of PC. Growth factors such as IGF and androgens may be important for 
progression. 
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For the cancer cells to metastasise, ie migrate out of the origin tissue, angiogenesis is 
required, which is yet another gained property of the cancer cells. 
1.1.7 PC initiation and development 
The initiation of PC is not understood in detail. Inflammation of the prostate has been 
suggested to increase the risk of later malignancy (Figure 1.2). Inflammation of 
prostate includes bacterial acute and chronic inflammation and conditions of 
extensive pelvic pain with no known infection. Inflammatory cells and excretion of 
cytokines, chemochines, prostaglandins and reactive oxygen and nitrogen species 
(ROS/RNS) may be related to increased risk and progression of PC (23). A condition 
of cellular growth, PIA (Proliferative inflammatory atrophy) frequently accompanies 
the inflammation. 
An early stage of PC is frequently associated with the loss of glutathione-S-
transferase (GST) P1 and has been termed prostatic intraepithelial neoplacia (PIN) 
(Figure 1.2). PIN is a neoplastic transformation of the secretory epithelium lining 
prostatic ducts and acini, with no extension through the basal lamina. High-grade PIN 
(HGPIN) is characterized by cells with more neoplastic traits than low-grade PIN, 
and has several features similar to PC. There is much evidence pointing to HGPIN as 
a frequent precursor of PC. The incidence and extent of PIN seems to increase with 
age (24). 
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Figure 1.2 Stages in PC development 
1.1.8 PC classification and treatment 
Risk assessment of PC is based on three categories, TNM classification,  Gleason 
score and PSA level.  
The TNM system (Classification of Malignant Tumours), is a system of classifying 
all cancers, and is routinely used for PC. The T refers to the extent of primary tumor; 
the N describes the status of regional lymph nodes and the M presence or not of 
distant metastases. An adenocarcinoma of the prostatic gland is classified as T1c 
when carcinoma cells are present on needle biopsy, while T3a describes a carcinoma 
with unilateral local extra prostatic extension.  
The Gleason system, defined in the 1960s and thus an established grading system of 
PC, is based on histological patterns of carcinoma cells in H&E-staining. The 
histological scores range from 2 to 10, and the score has been related to tumor size, 
margin status, and pathologic stage. It has also been linked to clinical end-points such 
as clinical stage, progression to metastatic disease, and survival (25). 
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Based on this system patients with localised disease are categorised in low, 
intermediate and high risk patients. In general radiotherapy is the preferred option for 
aggressive disease and surgery for less aggressive tumours. For patients in the low 
risk group active surveillance is an alternative to radical treatment 
PSA is a small glycoprotein that is produced in the epithelial cells of the prostate 
gland and is a constituent of semen which functions as a protease to make the semen 
more viscose, improving the sperm mobility and nutrient absorption. Small amounts 
of PSA are normally present in the blood. Damage to the basal layer and membrane 
separating the ducts from blood and lymph in the prostate may produce a leakage of 
PSA into the circulation. Increased PSA in blood is not specific for PC, but can be 
due to other diseases involving the epithelial cells of the prostate gland, but PSA in 
diagnosed PC is recognised as a good indicator of disease progression.  
Howver, PSA is not an opimal cancer specific biomarker, and although sensitive for 
PC it is also a biomarker of other prostate conditions. Therefore there has been a 
search for more specific biomarkers, and one promising may be the alpha-Methylacyl 
CoA Racemase (P504S) or AMACR (26). PSA increase indicates disease 
progression, while PSA decrease is interpreted as disease retreatment. 
In patients with elevated PSA levels biopsy is mandatory for diagnosis. In many 
patients PC is a slowly progressive disease while in others the clinical behaviour is 
very aggressive with early metastatic spread and eventually leading to death. It 
remains a challenge to distinguish between mild and aggressive cases at time of 
diagnosis. If radical local treatment is recommended, computer-assisted 
prostatectomy or radiotheraphy (including brackytheraphy) are the two options. 
Radical prostatectomy seems to improve survival compared to a ‘wait and see’ 
strategy. Addition of brackytheraphy to standard external radiotheraphy with 
installation of radioactive sources in the prostate gland, a higher dose is delivered to 
the tumour with no increased side-effects (27).  
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Some patients experience increasing PSA levels after the initial treatment which 
indicates progressive, metastatic disease (Figure 1.2). Taxan-based chemotheraphy 
may be the next treatment which has documented effect on survival in patients with 
verified metastatic disease (28). 
Androgen deprivation therapy, drugs that block androgen receptors in the whole body 
is used in advanced or metastatic disease, and 70-80 % responds initially (29). 
Unfortunately, advanced PC always develops into androgen independent disease 
(Figure 1.2) and the patients usually progress within 2 – 3 years. 
1.2 Oxidative stress 
Oxygen is vital for all aerobe organisms on earth. It is the electron acceptor in the 
electron transport chain of the mitochondria, and thus indispensable in energy 
production of aerobes. Its ability to accept and donate electrons gives oxygen its 
special properties (12). 
We often speak of oxygen radicals or reactive oxygen species (ROS). These are 
oxygen derivatives that react more or less spontaneous with other biomolecules, 
setting up a chain reaction where new reactive products are generated. The most 
reactive molecule is the hydroxyl radical, OH. It reacts at high rate constants with 
sugars, amino acids, lipids and nucleotides. Other less reactive ROS are superoxide 
O2- and hydrogen peroxide H2O2 (30). 
Oxidative phosphorylation is taking place over the mitochondria inner membrane to 
generate ATP (adenosine triphosphate). It has been estimated that 3-5% of the 
oxygen utilized in the mitochondria of a human is incompletely oxidized and thus 
potentially transformed to ROS (31). 
Free radicals are not always based on oxygen. Reactive nitrogen species (RNS) such 
as nitric oxide (NO) and nitrogen dioxide (NO2) are also free radicals. 
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The term oxidative stress was introduced by Sies in 1985 and defined by the same 
author in 1991 as a “disturbance in the prooxidant – antioxidant balance in favor of 
the former, leading to potential damage” (12). Later, oxidative stress has been 
described as “disturbed intracellular redox equilibrium” (32). 
The creation of RS (Reactive Species including both ROS and RNS) is caused by 
normal oxidative metabolism, various diseases, cigarette smoking, pollution, drugs, 
alcohol and radiation.  
RS need to be eliminated, and in healthy individuals one task of the antioxidant 
defence system is to scavenge the RS. However, in a condition of elevated RS 
generation the antioxidant defence system may become insufficient. RS will 
accumulate and subsequently impose damage to molecules such as nucleotides in 
RNA and DNA, lipids, sugars and proteins, and may result in a situation of oxidative 
stress. Oxidative stress is recognized in the pathogenesis of many chronic diseases 
such as inflammatory diseases, ischemic diseases, cancer, hemochromatosis, HIV 
(human immunodeficiency virus), emphysema, hypertension, preeclampsia, and 
neurodegenerative diseases (33). 
1.2.1 Defence system against oxidative damage 
Over the time of evolution, advanced systems of protection against oxygen toxicity 
has developed in bacteria, plants and animals, making up the antioxidant defences of 
living species. These systems are enzymes and scavenging compounds acting solely 
or interactively, and they may be endogenously derived or supplied by the diet. 
Halliwell and Gutteridge define the term antioxidant as “any substance that delays, 
prevents or removes oxidative damage to a target molecule” (12).  
To present a brief overview of the defence system against oxidative damage, this 
section is divided into two sections: endogenous antioxidants and dietary 
antioxidants. 
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Endogenous antioxidants 
The endogenous antioxidant defence system includes all endogenously derived 
substances that delay, prevent or remove oxidative damage to a molecule (12).   
Antioxidant enzymes 
The major antoxidant enzymes in eukaryotes are superoxide dismutase (SOD), 
catalase, glutathione peroxidase (GPx), glutathione reductase (GR), peroxiredoxins 
and thioredoxin reductase. 
SOD catalyses the conversion of superoxide anion to hydrogen peroxide and O2:  
 
There are three isoenzyme forms of SOD; a cytosolic Cu+-Zn2+ form (Cu-Zn-SOD), a 
Mn2+ form present in the mitochondria, manganese-containing superoxide dismutase 
(MnSOD) and an extra cellular Cu+-Zn2+ form (EC-SOD) (30).  
Catalase catalyses the reduction of hydrogen peroxide to water, preventing it to 
forming the hydroxyl radical in the Fenton/Haber-Weiss reactions. Catalase is 
abundant within in the peroxisomes: 
 
GPx and GR are superfamilies of enzymes in the glutathione metabolism. Reduced 
glutathione (GSH) acts as a substrate in the GPx catalysed conversion of hydrogen 
peroxide to water. Spontaneous or catalysed by GPx, two GSH molecules are 
oxidized (donating electrons) to form a single molecule: Glutathione disulfide or 
oxidized glutathione (GSSG). In this scavenging reaction, H2O2 will be reduced to 
water as illustrated below; lipid peroxides will be reduced to nontoxic alcohols (12). 
2 H2O2   2 H2O + O2 
catalase 
2 O2- +   + 2H  H2O2 +
SOD 
O 2 
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GSH  + HSG H O2 2
 
Glutathione reductase (GR) (requiring NADPH) regenerates GSSG to produce GSH, 
making up the glutathione redox cycle. 
Peroxiredoxins are a family of nonseleno-peroxidases that reduce hydrogen peroxide 
and organic peroxides. Thioredoxin reductase (TR) regenerates thioredoxin as 
described below.  
Non-enzymatic, endogenous antioxidants 
Low-molecular weight antioxidants 
Glutathione (GSH) is an abundant endogenous compound in the cellular protection 
against oxidative damage. GSH, gamma-glutamylcysteinylglycine, is a tripeptide 
composed of glutamate, cysteine and glycine. Glutathione is synthesized within all 
tissues, but the liver is the main site of synthesis and excretion of GSH to the 
bloodstream for supply to other tissues (34). Gamma-glutamyl-cysteine synthetase 
(GCS) catalyses the rate-limiting step in the GSH synthesis. GCS activity and 
substrate availability are the main determinants of the GSH synthesis within the cell. 
The homeostasis of GSH is maintained by GSH consumption, production and 
regeneration from the oxidized form (35). 
GSH and its oxidized form GSSG is a dominating redox pair within the cell. The 
glutathione redox cycle has been mentioned above. GSH also plays an important role 
in detoxification by conjugation within the xenobiotic metabolism (the mercapturate 
pathway). The family of GSTs catalyses xenobiotic compounds’ conjugation with 
GSH (12). GSH reacts non-enzymatically with the hydroxyl radical (OH) which is 
the highly reactive product of the Fenton reaction. It also reacts non- enzymatically 
with various cytotoxic nitric oxide products (35). 
GSSG 
Glutathione 
peroxidase 
2H O 2
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Uric acid is a powerful antioxidant abundant in human plasma. At physiological pH 
almost all uric acid is ionized to urate. Most species other than primates produce urate 
oxidase that break down the uric acid. In humans urate accumulate in plasma to a 
concentration of 0.2 – 0.4 mM (12). The loss of urate oxidase function may have 
been beneficial to primates, and it has been suggested that the increase in life span 
during human evolution could be due to the protective antioxidative action of urate in 
human plasma caused by this mutation (30). Urate has been shown to increase vastly 
after consumption of apples, possibly by fructose-mediated urate production (36). 
Polypeptides 
Thioredoxins (TRX) is a member of the thioredoxin protein superfamily and 
possesses strong reducing properties. It is able to reduce oxidized protein. TRX is 
upregulated in response to oxidative stress. TRX is itself regenerated by the enzyme 
thioredoxin reductase (TrxR) and NADPH (37). In addition to its ability to scavenge 
RS and thus influence the cellular redox status, TRX reduce cysteine residues that 
interact in cellular signalling pathways. In oxidative stress TRX translocate to the 
nucleus and modulate gene transcription (38). Other polypeptides acting as 
antioxidants are glutaredoxins and sulfiredoxins. 
Metal binding proteins 
Metals like Cu, Zn and Fe are essential in eukaryotes for the synthesis of various 
proteins involved in respiration, O2 transport and antioxidant defence. However, 
these metals also act as prooxidants and convert less reactive to more reactive 
species. Metallothioneins are metal binding low molecular weight thiol prote
sequestrate metal ions like Cu and Zn. Metallothioneins are found in the cytosol and 
nucleus of eukaryote cells, especially in liver, kidney and gut. Metallothioneins might 
also be antioxidants due to the high –SH content. Caeruloplasmin binds Cu and also 
exhibits ferroxidase activity; it oxidizes Fe(II) to Fe (III) and may facilitate iron 
loading on to transferrin and possibly ferritin (12).  
ins that 
Albumin is a small, highly soluble plasma protein at a concentration of about 40 
mg/ml. It contains an exposed –SH group at position 34 and contributes up to 500 
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µM to total plasma thiols. Albumin has multiple roles and could be an important 
extracellular antioxidant. It binds Cu tighly and Fe weakly. It also binds heam thereby 
protecting lipoproteins against haemdependent oxidation (12). 
Dietary antioxidants 
Fruits and vegetables are the major sources of dietary antioxidants. The antioxidants 
are produced by plants for protection against sun exposure during photosynthesis and 
other stress factors (12). The antioxidants vary in their structure, physical and 
chemical properties and are thus divided into groups. The most commonly known 
groups of dietary antioxidants are carotenoids, tocopherols, ascorbic acid (AA) and 
polyphenols (39). 
The carotenoid content in human bodies varies with the diet. Many carotenoids are 
colourful pigments of fruits and vegetables. Around 600 carotenoids have been 
identified in nature. Of these are 20 found in human blood and tissues (40). The 
carotenoids are insoluble in water, stored in fatty compartments within the cells and 
transported in the lipoproteins in blood. The carotenoids are all very good singlet O2 
quenchers in vitro, lycopene being the most efficient (12).  
Lycopene is the carotenoid that gives tomatoes their red colour. It is the most 
abundant antioxidant in tomatoes, and tomatoes are the best source to lycopene. In 
the intestine, lycopene is absorbed with fat, and transported to the circulation with 
fatty acids in chylomicrons (41). In raw tomatoes, lycopene is mostly present in the 
trans-form. During processing and heating, some of the lycopene is converted to cis-
isomers, which seem to be better absorbed. Processing during preparation may also 
increase the availability of lycopene from the tomato food matrix, where lycopene is 
tightly bound to macromolecules (41). 
The lipid soluble antioxidants scavenge RS in membranes and lipoproteins. Vitamin 
E plays an important antioxidant role in the lipofilic compartments of the cell. Two 
major related metabolite groups, the tocopherols (alpha-, beta-, gamma- and delta-) 
and the tocotrienols (alpha-, beta-, gamma- and delta-), constitute what is called 
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vitamin E. Of the eight isoforms with variable biologic activity, alpha-tocopherol is 
the most abundant in plasma, while tissue concentrations of alpha-tocopherol and 
gamma-tocopherol are comparable (42). 
Sources to Vitamin E in the diet are vegetable oils, vegetable-based spreads, nuts and 
seeds, certain fatty fish, egg yolk and whole grain cereals (43). Alpha-tocopherol 
content is high in sunflower seed and corn oil, while gamma-tocopherol is abundant 
in rapeseed oil (43). Gamma-tocopherol is the major form of vitamin E in the US diet 
(44). Gamma-tocopherol may act as a more effective scavenger of free radicals than 
alpha-tocopherol, while alpha-tocopherol is the metabolite primarily used in dietary 
supplements (44). Increased intake of alpha-tocopherol may suppress bioavailability 
of gamma-tocopherol (42). 
Prolonging shelf life of many foods, vitamin E comes naturally with plant oils, nuts 
and seeds. These products contain polyunsaturated fatty acids, and vitamin E protects 
them from going rancid. In a similar manner that vitamin E protects the food it may 
protect against oxidative damage in the human body by breaking the peroxyl chain 
reaction (30).  
Vitamin C or AA is a potent antioxidant and it acts as an electron donor. It is the most 
abundant chain breaking antioxidant in the water soluble compartments of the body 
and it readily scavenges the most potent ROS and RNS and thereby protecting lipids, 
proteins and DNA from oxidative damage. The ascorbyl radical that is produced in 
these reactions has low reactivity under physiological conditions, and this makes AA 
an ideal antioxidant. The ascorbyl radical may degenerate to AA and dehydroascorbic 
acid (DHAA) (12;39). 
Plant phenols comprise an enormous number of compounds, having in common an -
OH group attached to a benzene ring. The number of -OH groups and their position 
are determinants of the antioxidant properties. Polyphenols are made up of more than 
two monophenols (12). Bioavailability of polyphenols differs greatly; the absorption 
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is accompanied by extensive conjugation and metabolism such that the forms 
appearing in the blood are usually different from the forms found in food (39).  
1.2.2 The antioxidant network hypothesis 
Scavenging antioxidants may neutralize and stop the reactive chain by donating or 
accepting a single electron. Efficient antioxidants, like vitamins E and C, carotenoids 
and various plant phenols are believed to exert properties that impose a direct effect 
to prevent oxidative damage. In vitro, these substances are able to break the chain 
reaction initiated by oxidation. The scavengers can be divided into lipid phase and 
aqueous phase antioxidants, indicating in which macromolecules and compartments 
they may exert their effect. 
As presented by Packer et al. (45), it is likely that the chain breaking antioxidants 
interact in vivo (45) (Figure 1.3). A chain of antioxidants could reduce and oxidize 
each other according to the redox potentials of the substances. Each successive redox 
reaction could transfer the radical challenge to a molecule with lower oxidation 
potential, thereby being less reactive. Subsequently the radical challenge would be 
transferred to molecules that are easily eliminated from the body, like for instance 
AA and phenols. AOX-n and AOX-n radical denotes arbitrary antioxidant redox pairs 
with adequate redox potentials. 
As an example, ascorbate may regenerate the tocopheryl radical at the aqueous-lipid 
interface and thus producing alpha-tocopherol. In a similar way, glutathione may 
recycle ascorbate from dehydroascorbate (30). 
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Figure 1.3 The antioxidant defence network, modified after Packer et al. (45) 
1.2.3 Oxidative molecular damage 
Oxidation may damage molecules such as DNA, lipids and proteins. 
There are approximately 5x1013 cells in a human body. It has been estimated that 
there are a few hundred oxidations in the DNA of each cell per day. Direct damage to 
DNA by RS can affect the purine (adenine, guanine) or pyrimidine (thymine, 
cytosine) bases and the deoxyribose sugar. DNA attacked by for example hydroxyl 
radical (OH) generates a whole range of base and sugar modification products. 
Guanine has the lowest oxidative potential; therefore the highest rate of oxidation is 
on this base. The cells own repair mechanisms are of vital importance to avoid 
damaging mutations to DNA. Base exision repair (BER) is the most common method 
to remove oxidative damage (12). 
Lipid peroxidation has been described as “oxidative deterioration of polyunsaturated 
lipids”. Fatty acids, and especially polyunsaturated fatty acids (PUFAs) going rancid 
have been a problem as long as foods containing these fatty acids (dairies, oils and 
fatty fish) have been stored (12). 
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PUFAs with double bindings on either side of the carbon atom, are more vulnerable 
to oxidation than others, thus the oxidizability of EPA (eicosapentaenoic acid) and 
DHA (docosahexaenoic acid) is much greater than that of linolenic acid (12). Lipid 
peroxidation may be initiated by adding a hydroxyl radical or nitrogen oxide to a 
methylene group or by abstracting a hydrogen atom from a methylene group. The 
carbon radical will react with O2 to give a peroxyl radical:  
R + O2 -> ROO 
Peroxyl radicals may abstract an hydrogen atom (H) from an adjacent fatty acid, and 
thus a propagation of lipid peroxidation may continue to generate multiple peroxide 
molecules. A series of damaging actions on the cell membranes, increasing leakiness 
and reducing function of membrane proteins may result. Membranes may even 
disintegrate (12). 
Oxidative protein damage may occur as a direct attack of RS or as secondary damage 
caused by end-products of lipid peroxidation. Damage to cellular proteins may be 
serious and irreversible. For example damaged DNA repair enzymes could increase 
the mutation frequency. Accumulation of damaged proteins could lead to cell death. 
Damaged proteins are therefore taken care of by the cell, removed by lysosymes or 
proteasomes (12). 
1.3 Oxidative stress and carcinogenesis 
There are strong indications that carcinogenesis is related to oxidative stress. Both 
elevated RS (by cigarette smoking) and impaired antioxidant defence, (eg CuZnSOD 
knockout mice) show increased risk of cancer development (46). 
Increase in oxidative stress is associated with ageing, and the largest single risk factor 
of cancer is age. Interestingly, the cancer risk is not clearly elevated in diseases with 
chronic oxidative stress like rheumatoid arthritis and diabetes (12). 
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In the past decade awareness has grown around the importance of the balance 
between oxidation and reduction within cells. The oxidative state of the cells is of 
vital importance not only in disease but also in health. 
In cell culture, one may characterize cell growth, proliferation, apoptosis and necrosis 
after exposing cells to increasing levels of RS. When exposing the cells to increasing 
levels of RS, the cellular GSH/GSSG ratio may also be measured as an indicator of 
oxidative stress. With increasing levels of RS, the GSH/GSSG ratio decreases due to 
lower GSH and higher GSSG.  
How cells cope with increasing oxidative stress was characterised by Halliwell and 
Gutteridge (12) in five levels:  
1) In a healthy, resting cell, the GSH/GSSG ratio is high due to a low quantity of 
GSSG.  
2) Mild oxidative stress increase intracellular Ca2+, protein phosphorylation and 
proliferation.  
3) Further increase in oxidation give an adaptive response featured by increased 
transcription of protective enzymes and proteins, and slowing down cell cycle 
to allow DNA repair.  
4) Exposed to even greater oxidation, the cell may undergo apoptosis due to 
DNA injury and other non repairable damage.  
5) Severe oxidative stress result in necrosis, and thus transition metals and other 
oxidizing factors may be released to the neighboring cells and increase the 
oxidation even further (12).  
According to Halliwell and Gutteridge (12), carcinogenesis and oxidative stress may 
interact in many ways, but “the balance of evidence supports the view that oxidative 
DNA damage is involved in the carcinogenesis, whatever carcinogen started the 
process” (12). 
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Oxidative stress may modulate all the stages of carcinogenesis. In cancer initiation, 
oxidative stress may increase the rate of oxidation in DNA and RNA leading to base 
modifications and mutations. In smokers, who have increased risk of some cancers, 
higher rates of urinary 8-hydroxy-2-deoxyguanosine (8OHdG) excretion have been 
measured. Elevated levels of 8OHdG which may result from oxidative stress have 
been found in human cancer tissue. Cause and effect is however not possible to 
distinguish (47). Persistent mild oxidative stress may stimulate cell growth and 
proliferation, perhaps contributing to clonal expansion and proliferation of tumor 
cells (12).  
Role of oxidative stress in PC 
Oxidative stress is assumed to play a role in PC. Some examples that indicate a 
connection are given below. 
The loss of expression (silencing) of the GSTP1 gene by hyper methylation is an 
early and the most common (>90%) genetic alteration reported to date in PC (48). PC 
cells with loss of GSTP1 function seem to survive and proliferate better than cells 
that express GSTP1 properties when exposed to oxidative stress. The family of 
glutathione –S- transferases is important in the endogenous defence against oxidative 
damage (49). 
 In a group of thirtytwo PC patients, Chen et al. (50) measured reduction of 8OHdG 
in leucocytes and prostate tissue after a three weeks intervention with tomato-based 
pasta dishes. Compared to pre-intervention, leukocyte 8OHdG was reduced by 21.3 
% after the intervention. 8OHdG in prostate tissue was 28.3% lower in the patients 
after intervention compared to a randomly selected control group (50). 
An enzyme having a key function upon peroxisomal oksidation of fatty acids, alfa-
methyl-acyl-CoA-racemase (AMACR), is up-regulated in tumor tissue compared to 
normal tissue. Elevated AMACR activity may lead to increased release of 
hydogenperoxide that again may induce DNA damage (51). 
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1.4 Dietary factors that may influence PC incidence and 
progression 
The risk of PC varies between populations, and the variation may be attributed to 
dietary differences. The population of men from Crete, as documented by Ancel Keys 
in the classic Seven Countries Study in the 1960s, had the lowest rate of 
cardiovascular disease and cancer in this multi center study, even lower than the 
Japanese participants. The diet of Crete has a omega-6 to omega-3 fatty acid ratio of 
2:1, while western countries are estimated at ratios around 15:1. Tomatoes, onion, 
grape, garlic, grains, seeds, wild plants and herbs are staples in this diet, in addition to 
large amounts of olive oil (52). However, from epidemiology, fruits and vegetable 
intake in general seems to have a weak or no effect on PC prevention (12). 
Furthermore, Japanese and Eskimo men with high intakes of marine omega -3 fatty 
acids have a low risk of PC (53). 
There are vast dietary differences between populations of low (East Asia) and high 
(Western) PC risk. The East Asian diets are traditionally low in energy and dietary 
fat. The diets include isoflavones (phytoestrogens) from soy beans, polyphenols from 
green tea, and are low in meat, milk and dairy products. The Japanese diet is rich in 
marine fatty acids, and traditional Asian diets are prepared by boiling or steaming, 
not grilling or smoking (54). 
The amount of literature on nutrition and cancer prevention has increased since the 
mid – 1990s. Single food items and individual nutrients have been investigated. The 
report “Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global 
Perspective” was issued in November 2007 (11), also known as The Second Expert 
Report, is the most comprehensive report of the connection between diet and cancer 
risk published to date. The report is a joint effort by the World Cancer Research Fund 
and American Institute for Cancer Research. Through what is called Systematic 
Literature Reviews a structured methodology was built that combine the findings 
from individual studies into classification of each food or nutrient and its possible 
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prevention of cancer at various sites. The nutrients’ protective or causative properties 
are classified into “convincing”, “probable”, “limited-suggestive” and “limited –no 
conclusion” (11).  
Substantial effect on risk unlikely
Limited-suggestive
Probable
Convincing
Decreases risk
Processed meat
Milk and dairy products
Diets high in calcium
Pulses, legumes
Foods containing vitamin E
Alpha-tocopherol
Foods containing lycopene
Foods containing selenium
Selenium
Increases risk
Foods containing beta-carotene
Beta-carotene
Figure 1.4 Matrix displaying the strength of evidence causally relating food and risk of PC, as 
judged by the panel of the Second Expert Report by November 2007 (11) 
To date, no nutrient regarding PC has been classified as convincing. The Second 
Expert Report stated that foods containing lycopene, foods containing selenium and 
selenium supplements probably reduce the risk of PC (Figure 1.4). Diets high in 
calcium probably increase the risk, while there is limited suggestive evidence that 
pulses (soya), foods containing vitamin E and alpha-tocopherol (50 mg per day) 
reduce the risk of PC. Processed meat (meats preserved by smoking, curing, salting or 
chemicals) and milk and dairy products are limited suggestive in increasing the risk. 
Figure 1.4 displays a graphical summary of the most studied foods and nutrients and 
their proposed effects on PC.  
The list of foods classified as “limited – no conclusion” (not shown) is very long and 
includes tea, fruits, non-starchy vegetables, fish and vitamin D (11). The grading of 
the uncertainty with respect to effect reflects the amount and quality of 
documentation available for each food and nutrient. 
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The following sections about nutrients and PC risk are arranged according to The 
Second Expert Report’s classification by November 2007, with emphasis on 
protection.  
1.4.1 Probable and suggestive decreased risk 
Tomatoes and lycopene 
The Second Expert Report states that “Foods containing lycopene probably protect 
against PC” (11). 
From epidemiology we know that consumption of tomato products is inversely 
correlated to PC risk. Consumption of tomato products over time result in 
accumulation of lycopene in prostate tissue and significantly increased levels of 
lycopene in serum. Further investigations have shown that lycopene blood levels are 
inversely correlated to PC risk (55). Lycopene half-life in human plasma has been 
reported to vary between 5 to 9 days (56). 
Studies of PC cell lines have shown that lycopene possess several anti-carcinogenic 
effects. Areas of interest include: 1) Antioxidant function 2) Inhibition of cell cycle 
progression 3) Induction of apoptosis 4) Increase in gap-junctional communication 5) 
Reduced IGF-1 signal transduction 6) Up regulation of phase 2 enzymes 7) Reduce 
androgen effect (55). 
Human PC interventions  
Eating tomatoes may prevent men from contracting PC. Tomatoes, given to PC 
patients, could also dampen the disease or slow down the carcinogenesis. 
Kucuk et al. (57) found that 30 mg lycopene daily for 3 weeks was sufficient to 
modulate PC, and significantly increase connexin 43 (connexins are gap juntional 
proteins that are essential in cell-to-cell communication) and decrease IGF-1. The 
study by Chen et al. (50) has already been mentioned above. In addition to the effect 
on 8OHdG, PSA was reduced significantly in this trial (50). 
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More clinical PC trials are discussed in Chapter 6, the section “Tomato effect on 
PSA”. Table 6.1 presents a list of six human PC tomato/lycopene trials. 
Selenium 
Selenium (Se) is an essential component in the glutathione family of enzymes, and 
low dietary levels are connected to increased risk of some cancers (11). According to 
the 2007 Second Expert Report (11), both foods containing selenium and selenium 
supplementation may protect against PC. 
The main dietary sources of selenium in the Norwegian diet are fish, wheat and dairy 
products (58-60). Wheat imported from the North America has high selenium 
content, whereas wheat grown in the Nordic countries, with the exception of Finland, 
has low selenium content. In Finland, agricultural fertilizers have been enriched with 
selenium from 1984, and the average serum selenium concentration (men and 
women) in Finland is 100-120µg/L compared to Sweden and Denmark where it is 70-
80µg/L (43). Interestingly, the age adjusted PC incidence and death numbers in 
Finland are low compared to the other Nordic countries (4). 
Selenium may inhibit carinogenesis via many possible mechanisms. Cell models of 
PC have shown that Se inhibit growth, apoptosis and PSA excretion in a dose 
dependent manner (61). In experimental animal models supplementation with Se has 
been shown to reduce oxidative damage and induce apoptosis in PC cells (62). 
Studies in healthy men have shown that supplementation with 200 µg Se per day 
significantly increase Se levels and have a significant effect on oxidative damage in 
prostate tissue (63). 
In Norway, the daily recommended intake of Se for men is 50 µg (64). Selenium 
supplementation dosageing must be careful, because the maximum safe intake is 
thought to be around 15µg/kg body weight, but could be lower in some sensitive 
individuals (65). 
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Supplementation with selenium and vitamin E has been thoroughly investigated in 
the  study called Selenium and Vitamin E Cancer Prevention Trial (SELECT), where 
35533 men were recruited and randomly assigned to 4 groups (selenium, vitamin E, 
selenium + vitamin E, and placebo) in a double-blind fashion. The selenium dose was 
200µg daily. Selenium supplementation revealed no effect on PC, while a small 
increase in diabetes type 2 among those who received selenium was observed (66). 
Soy beans and isoflavones 
Few and contradictory results have been published on soy and PC. Soy contains large 
amounts of isoflavones like genistein and daidzein and the observed protective effect 
has been attributed to this group of substances. A meta-analysis consisting of 2 cohort 
studies and 6 case-control studies showed an inverse relation between soy intake as 
food and risk of developing PC (67).  
Dalais et al. (68) observed PSA reduction of 12.7 % after 3-4 weeks of soy and a 10 
% PSA reduction by soy and linseed enriched diet versus wheatbread diet in PC 
patients. Kumar et al. (69) observed a trend towards a reduction in PSA after soy 
supplementation in early stage PC patients (69). A significant reduction in PSA 
percentage increase was observed in PC patients supplemented with soy for 5-6 
months (70). Long time supplementation with soy in healty elderly men or men with 
increasing PSA has been effective to reduce PSA (71-73).  
Vitamin E 
There are several studies investigating the relationship between alpha-tocopherol and 
incidence of PC. 
Results from the ATBC Alpha-Tocopherol, Beta-Carotene Cancer prevention study 
with 29133 Finnish participants; male smokers aged 50 to 69 years; showed that a 
daily supplement of 50 mg vit E (alpha-tocopherol) reduced the risk of PC. In the 
same group, however, more deaths from hemorrhagic stroke were observed (74). 
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In the United States Health Professional Study cohort (observational study of 47780 
healthy males) no general association between dietary vitamin E supplementation and 
risk of PC was found. However, a decreased risk of aggressive PC was found among 
smokers taking vitamin E supplements (75), which was consistent with the Finnish 
trial. In a nested case-control study of blood donors, 117 PC patients and 233 
controls, an inverse association was found between increased serum levels of alpha-
tocopherol and selenium, but this was connected to high plasma concentration of 
gamma-tocopherol.  
The Physicians Health Study II, a Randomised Controlled Trial including 14641 
participants showed no effect of long term vitamin E supplementation in prevention 
of PC (76). 
The SELECT study (described in the selenium chapter above) recently discontinued. 
No evidence of benefit from vitamin E (alpha-tocopherol) was demonstrated but 
rather a small but not statistically significant increase in PC among the patients who 
received vitamin E was detected (66). Yearly PSA testing by the participants on their 
own intiative probably removed diagnosed cases from the study at an early stage of 
disease and because of this, effect from the intervention on disease progression was 
probably not seen. However, more information from the SELECT and Physicians 
health study randomized controlled trials are expected, and results from subgroup 
analyses like smokers, genetic factors and baseline serum levels may reveal 
modifications to these initial results (77). 
1.4.2 Probable and suggestive increased risk 
Processed meat 
Processed meat as denoted in The Second Expert Report includes preserved meat 
(salted and smoked), meat products, hamburgers, ham, salami, bacon, cured meat and 
sausage as an overall category. There is limited evidence suggesting that processed 
meat is a cause of PC. Nitrates added as preservatives and produced in gastric acid 
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may contribute to N-nitroso componds that are suspected mutagens and carcinogens. 
High levels of salt and nitrite may accompany meat, while meats cooked at high 
temperatures may contain heterocyclic amines and polycyclic aromatic hydrocarbons 
(11). 
Calcium 
Many epidemiologic studies have reported a positive association between dairy 
products and PC. Calcium or saturated fatty acids in dairy products have been 
suspected as the causative agent (78). However, pooled data from 45 observational 
studies did not support an association between dairy product use and an increased risk 
of PC (79). 
In Japan, where the intake of dairy products, calcium, and saturated fatty acids are 
low and the incidence of PC is low, a population-based prospective study was 
conducted enrolling 43435 Japanese men ages 45 to 74 years. Dairy products were 
associated with a dose-dependent increase in the risk of PC. A statistically significant 
increase in risk was observed for both calcium and saturated fatty acid, but the 
associations for these were attenuated after controlling for potential confounding 
factors (80). 
The European Prospective Investigation into Cancer and Nutrition examined 
consumption of animal foods, protein and calcium in relation to risk of PC among 
142251 men. After an average follow-up time of 8.7 years, there were 2727 incident 
cases of PC. A high intake of dairy protein was associated with an increased risk, 
with a hazard ratio for the top versus the bottom fifth of intake of 1.22 (95% 
confidence interval (CI): 1.07 - 1.41, P (trend) = 0.02). Calcium from dairy products 
was also positively associated with risk, but not calcium from other foods. The results 
supported the hypothesis that a high intake of protein or calcium from dairy products 
may increase the risk for PC (81). 
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1.4.3 Inconclusive 
Grape juice 
Important polyphenols in grapes and grape juice are resveratrol, quercetin, catechin 
and anthocyanins. 
Resveratrol has been shown improve health and survival of mice on a high-calorie 
diet (82). Resveratrol is a stilbene found in grapes and one of the most important 
antioxidants in red wine. Resveratrol may be an important contributor to “the french 
paradox” ie that a moderate red wine consumption reduce the mortality from 
cardiovascular disease and some cancers in spite of high intake of saturated fat and 
red meat in the French population. Resveratrol may regulate proteines involved in 
DNA syntesis and cell cycle like p53 (tumour protein 53), Rb/E2F, cyclins, CDKs 
(cyclin-dependent kinases) and inhibitors of these. Resveratrol also may reduce the 
activity of transcription factors involved in proliferation and stress response, such as 
NF-kB (Nuclear factor kappaB), AP1 (Activator Protein 1) and Egr1 (Early Growth 
Response Protein 1). In cell models for PC, resveratrol has shown favourable effects 
in relation to PSA excretion, cell cycle- and proliferation specific genes (83). 
Resveratrol may also induce apoptosis (84). 
Pomegranate juice 
Pomegranates contain very high levels of antioxidants (85;86), and in recent years 
several studies have been published that indicate favourable effects of this fruit. 
Pomegranate (Punica granatum) is a good source of at least two polyphenols: 
anthocyanines, giving the red colour, and ellagitannins, both being active 
antioxidants (87). The ellagitannin abundant in pomegranates is punicalagin which is 
the largest molecular weight polyphenol known. According to Heber (88) 
ellagitannins are hydrolysed to ellagic acid before absorption in the gut. Heber claims 
that ellagitannins and not antocyanidins account for the anticarcinogenic properties of 
pomegranates. Being a denominator of inflammation, the NF-kB transcription factor 
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is found to be constitutively upregulated in PC cells. Ellagitannins are seen to inhibit 
the activation of NF-kB and other inflammatory agents (88). 
Malik et al. (89) have shown that favourable effects from pomegranate extracts on PC 
both in vivo and in vitro. In an experimental mouse model the animals were divided 
into groups where one group received pure water and the two other groups were 
served water enriched with pomegranate extract of 0.1% and 0.2% respectively. The 
pomegranate animals had significantly smaller tumorsizes and the strongest 
concentration was most effective. One month after the tumorinoculation the size of 
the tumors in the 0.2% group was approximately half as big as in the controls. The 
PSA level was significantly reduced in both pomegranate groups (89). 
Recent reports have indicated that pomegranate juice may interfere with the 
cytochrome p450 system of xenobiotic detoxification and excretion. Experiments on 
human hepatocytes and rodents have shown that CYP3A4 may be inhibited by 
pomegranate juice. It was found that pomegranate juice consumption decreased total 
hepatic cytochrome P450 (CYP) content as well as the expression of CYP1A2 and 
CYP3A. It was suggested that prevention of procarcinogen activation through CYP 
activity/expression inhibition may be involved in pomegranate juices’ effect on tumor 
initiation, promotion, and progression (90-92). A study on healthy volunteers did 
however not produce the same effect on humans (93). 
One clinical trial has been conducted on PC patients to date (94). Results from this 
trial were published in 2007. Eligible patients had a detectable PSA > 0.2 and < 5 
ng/mL and Gleason score < 7, which may be characteristic of localised PC. The 
patients received 8 oz (237 ml) of pomegranate juice daily over two years or more. It 
showed a significant increase in PSA doubling time from a mean of 15 months at 
baseline to 54 months post-treatment (p < 0.001) (94). 
Tea 
Some epidemiological studies have indicated that people who regularly consume tea 
have a decreased risk of PC (95-97). But in a retrospective cohort study using 
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participants in the 1970-1972 Nutrition Canada Survey, no association was observed 
between tea (predominantly black tea) intake and PC (98). The Second Expert Report 
indicates that black tea suggestively prevent PC, but according to this comprehensive 
report there was no evidence of association between green tea intake measured in 
cups per day and PC (11). However, Jian et al. (95) conducting a retrospective case-
control study of tea intake in China showed strong protection from (mainly) green tea 
consumption over many years, and high daily intake (> 1 litre) (95). 
Bettuzzi et al. (99) supplied men, with HGPIN, of whom 30% were expected to 
develop PC during one year with 600 mg/d of green tea cathechins in capsules. The 
trial lasted for one year, and in the control group 30% of the patients developed 
cancer while in the intervention group only 3% developed cancer (99). 
The active substance that may impose an anticarcinogenic effect is possibly 
epigallocatechin-3-gallate, a polyphenol constituting around 1/3 of the total 
polyphenol content in green tea and up to 10 % of the total polyphenols in black tea. 
Oral infusion of green tea polyphenols analogous to 6 cups daily have been shown to 
inhibit PC in a transgenic mouse model of PC (TRAMP), and numerous mechanisms 
for green tea effect on PC have been suggested from cell culture studies: influence on 
androgen metabolism, PSA decrease, induction of apoptosis (via p53 and NF-kB) and 
improved cell cycle control (100;101). 
High dose administration of green tea polyphenols to patients with advanced 
androgen independent PC showed minimal effect (102;103). 
Fatty fish and omega-3  
Long chained omega-3 fatty acids are unique nutrients in fish. Epidemiological 
studies and case-control studies have shown an inverse relationship between omega-3 
fatty acids (EPA and DHA) intake and risk of total and aggressive PC (104-107). 
Freeman et al. (105) have showed an inverse connection between omega-3 fatty acids 
measured in prostate tissue and spreading to adjacent organs. Few randomized trials 
with omega-3 supplement have studied the effect on patients with PC. One study 
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(108) report that intervention with omega-3 fatty acids have no effect on serum PSA, 
however a reduction in cyclooxygenase 2 (COX-2) expression and an increase in the 
omega-3:omega-6 ratio was observed (108). Inhibition of COX-2 expression blocks 
inflammatory effects and may be useful for prevention or theraphy of PC (101). 
1.4.4 Additive or synergistic effect 
Assuming that the various anticarcinogenic food substances act differently, it could 
be favourable to combine substances to achieve a greater effect than one could obtain 
from one substance alone. An additive effect would be the sum of two effects, but 
one could also imagine a synergistic effect, ie that two or more substances together 
give a greater effect than just the sum of the individual effects. Such effects could be 
present in natural diets. 
1.5 Foods versus supplements 
According to Parcelsus, “All substances are poisons; there is none which is not a 
poison. The right dose differentiates a poison and a remedy.” Considerable 
documentation has shown that supplementing well nourished human populations with 
high concentrations of single antioxidants give no cancer prevention, rather the 
opposite (109). Interventions with synthetic antioxidant supplements have failed to 
show a protective effect, and some have even increased mortality. In October 2008, 
the SELECT study terminated the selenium and vitamin E trial due to no effect on PC 
prevention and possible adverse effects (110). However, the baseline serum selenium 
average of all groups in the US study population was approx 135 μg/L. This is much 
higher than the Nordic values (65), indicating that the population baseline serum level 
should be taken into account when the results are interpreted for Norwegian or 
Nordic populations. 
Antioxidant supplements are not subjected to the same rigorous toxicity studies as 
other pharmaceutical agents (109). Like other chemical substances, vitamins and 
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minerals cause adverse and toxic effects if consumed in excessive amounts (43). 
However, adverse effects from supplementation studies with essential vitamins and 
minerals have occurred at doses well below established upper intake level. Figure 1.5 
below displays possible relationships between antioxidant dose and risk of disease.  
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Figure 1.5 Possible relationships between antioxidant dose and risk of disease 
The failure of the antioxidant supplementation interventions does not necessarily lead 
to the conclusion that the dietary antioxidants have no effect on carcinogenesis. 
However, there seem to be important differences between (1) natural plant foods 
containing a variety of substances and (2) capsules with a high concentration of a 
single antioxidant metabolite. 
(1) Unprocessed plant foods supply tissues with a blend of substances whereof many 
possess antioxidant properties. Such a combination is only obtainable from natural 
foods, fruits and vegetables and not from synthetic supplements. According to the 
hypothesis of the antioxidant defence network, the substances interact due to diverse 
chemical properties and reduction potentials. These networks could be very delicate 
and well balanced. 
  43
(2) Capsules with a high dose of a single antioxidant metabolite may increase the 
tissue level of this single substance to a level that could bring the antioxidant network 
out of balance. Great individual variation could be expected and adverse effects may 
only affect susceptible individuals. 
1.6 Diet and gene interaction 
Studies of relationships between dietary components and cancer risk often give 
contradictory results. This may be due to the weakness of the dietary assessment 
methods, but could also be caused by unrecognized heterogeneity of the study 
populations, such as genetic polymorphisms. Interaction between specific 
polymorphisms and individual food components or nutrients could mask associations 
(111). In recent years many reports of such connection between nutrients and genes 
have been reported, and below are some examples that could indicate the importance 
of allele variants in nutrition research: 
Goodman et al. (112) reported an effect modulation by plasma antioxidants, the 
XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1) 
genotype, lycopene intake and PC risk. The XRCC1 gene is involved in the BER 
mechanisms and their results indicate that the association between lycopene and PC is 
complex and may involve other antioxidants (112). 
A Swedish study (113) reported that frequent consumption of fatty fish and marine 
fatty acids appears to reduce the risk of PC, and this association seems to be modified 
by genetic variation in the COX-2 gene. A strong protective effect of fatty fish intake 
was shown in the carriers of the variant allele but not among those carrying the 
common allele (113). 
There have been inconsistent results from the role of trans-fatty acid intake on risk of 
PC. Liu et al. (114) suggest that RNASEL genotype may modulate the disease risk 
associated with total trans-fatty acid intake. Their study indicated that for men with 
the R462Q RR genotype, total trans-fatty acid intake was not associated with disease 
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risk, while among men with the QQ/RQ genotype, the association between total 
trans-fatty acid intake and PC was substantially stronger (114). 
Much research has addressed polymorphisms in genes related to antioxidant defence 
systems and the xenobiotic metabolism, but inconsistent results have been reported 
with respect to susceptibility for PC. There are many possible confounding factors to 
such studies, and the genetic makeup differs between study populations. Katoh et al. 
(115) conclude that GSTM1, GSTT1 and GSTP1 are unlikely to be major 
determinants of PC susceptibility. However, according to Traka et al. (116), broccoli 
consumption seems to be protective in men that are GSTM1 positive compared to 
those who are GSTM1 null. 
1.7 Oxidative stress biomarkers 
Numerous methods for measurement of oxidative stress have been developed and 
tested. Jones (117) classifies five general approaches to potential biomarkers: 1) 
antioxidant enzymes, 2) low molecular weight antioxidants, 3) the balance between 
pro-oxidants and anti-oxidants, 4) oxidants, 5) products of oxidative damage (117). A 
sixth class is to measure 6) the total antioxidant capacity (118).  
At present, there are no golden standards for measuring oxidative stress in clinical 
practice, and reference values lacking. There are, however, many potential 
biomarkers. The following selection will be studied in this master thesis: 
 Antioxidant related enzyme: Gamma glutamyl transferase (GGT) 
 Low molecular weight antioxidants: Glutathione (GSH), Ascorbic acid (AA)  
o Body thiol pool: Cysteine 
 Products of oxidative damage to 
o DNA: 8-hydroxy-2’-deoxyguanosine (8OHdG)  
o Lipids: Hexanoyl-epsilon-lysine (HEL), Diacrons reactive oxygen 
metabolites test (d-ROMs test) 
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 Total antioxidant capacity: ferric reducing ability of plasma (FRAP), modified 
FRAP (mFRAP). 
1.7.1 GGT 
Cellbound gamma-glutamyl transferase or gamma-glutamyltranspeptidase, GGT, is 
an enzyme facing outwards on the plasma membrane of most cell types. GGT also 
exists as free fraction in plasma. A major task of GGT is to catalyse the breakdown of 
free GSH and GSSG which is excreted from the cell. The metabolites are then ready 
to be transported back into the cell to serve as substrates for new GSH synthesis. 
GGT is especially numerous in kidney cells and in the lungs (12). 
In the clinic, serum GGT is established as a measure of liver disease and liver toxicity 
induced by alcohol and drugs. Moderate increase of serum GGT is seen in hepatitis, 
liver metastases, pancreatitis and renal diseases. Epidemiologic studies show that 
serum GGT are correlated with biomarkers of inflammation and oxidative stress, such 
as fibrinogen, CRP and F2-isoprostanes (119). 
Epidemiological findings suggests that serum GGT within normal ranges could be a 
predictive biomarker of oxidative stress related disease, and thus could be used as an 
early biomarker of diseases such as cancer and cardiovascular disease (119). 
A pro-oxidative effect of GGT is seen in model studies (120). The reactive thiol 
glycyl-cystein metabolite, resulting from the GGT catalysed reaction, is more 
reducing than GSH, and will thus reduce Fe3+ to Fe2+ more readily, generating 
hydrogen peroxide. 
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Up regulation of GGT due to increased levels of extra cellular GSH/GSSG could thus 
be part of a vicious cycle where the oxidative stress originating from other causes is 
reinforced (120). 
GGT seems to be a very promising biomarker of oxidative stress. 
1.7.2 GSH 
GSH and the GSH related enzymes were described in section 1.2.1 “Defence system 
against oxidative damage.”  
Plasma GSH is rapidly metabolized by GGT, discussed in a separate section. Its half-
life is a few minutes. The turnover of GSH and the transcription of glutathione 
reductase (GR) increases in response to oxidative and nitrosative stress. Much 
studied, 4-hydroxy-2-trans-nonenal (HNE), a lipid peroxidation end product is shown 
to up regulate GSH synthesis (12).  
The main mechanisms for upregulation are (figure 1.6): a) ROS/RNS, b) cysteine 
and glutamate availability, c) GSH depletion and d) food factors that inhibit NO 
synthase (not shown in the figure) (121).  
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Figure 1.6 Regulation of glutation synthesis. The main mechanisms for upregulation are 
ROS/RNS, cysteine and glutamate availability, GSH depletion andfood factors that inhibit NO 
synthase (not illustrated) 
The intracellular GSH content is known to be influenced by oxidative stress related 
diseases and conditions. Connection has been shown between the GSH levels and 
susceptibility and outcome in diseases such as cancer, neurodegenerative diseases, 
cystic fibrosis, and in ageing (122). Bøhn et al. (123) found that lowered extra 
cellular (plasma) GSH levels, as a measure of general oxidative stress in patients with 
head and neck squamous cell carcinoma, predicted the disease outcome (123). 
The intracellular ratio GSH:GSSG is normally >100 under normal physiologic 
conditions. Within cells, the glutathione concentration varies from 0.5 to 10 mmol/L 
while the extra cellular concentration is much lower: 2 – 20 µmol/L in plasma. GSH 
is metabolized before excretion in urine, so urine may not be a good medium for 
GSH measurement. Plasma or blood cells could be of interest. Virtually all GSH in 
full blood is contained within cells. Thus, the plasma level of GSH is low and 
variable (12). 
↑GR 
↑ROS/RNS 
gsh 
L-cysteine 
↑gsh synthesis 
gssg 
glutamate 
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1.7.3 Cysteine 
Cysteine is part of the GSH tripeptide, and the thiol group of cysteine is what gives 
GSH its unique property in the oxidative stress defence. 
Cysteine is together with methionine the sulphur-containing amino acids normally 
consumed in the diet. Methionine is considered an essential amino acid and is a 
precursor of homocysteine and cysteine.  
Absorption of the amino acids from the diet is highly efficient, and after absorption 
from the gut, the amino acids enter the portal vein and a substantial proportion of the 
sulphur amino acids are removed by the first pass through the liver for protein and 
GSH synthesis. Cysteine is present as CySH (thiol or reduced form), disulfide 
(cystine or CySSCy) and protein bound (PSSCy). Mean total cysteine plasma levels 
in healthy individuals range from 220 to 320 µmol/L (124).  
1.7.4 Total ascorbic acid and dehydroascorbic acid 
Ascorbic acid (AA) or vitamin C was isolated in 1928. Deficiency of AA with plasma 
levels below 11 µmol/L leads to scurvy which is characterized by spongy, bleeding 
gums, tooth loss, poor wound healing and swollen weakened limbs. Prospective 
studies of AA have shown increased cardiovascular, cancer and all cause mortality in 
subjects of the lowest plasma concentrations. The mean cut-off point for clearly 
lowered risk has been found to be a plasma concentration of 32 µmol/L. This 
corresponds to a daily intake of approximately 60 mg/d in men. Adding 25% for 
inter-individual variation gives the Nordic recommended intake of 75 mg, 
corresponding to a plasma concentration of 40 µmol/L. Also according to the Nordic 
Council of ministers’ recommendations of 2004, 100 mg intake shows a saturation of 
blood cells and the plasma level will be 50 – 60 µmol/L. Very large doses (2.5 grams) 
are seen to increase the plasma levels up to 80 mmol/L (43).  
Most primates are able to synthesise AA from glucose exept for humans, fruit-eating 
bats and guinea pig.  
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The ratio between DHAA and total AA has been suggested as a predictor of oxidative 
stress (125). Smokers have almost double turn-over of non-smokers, and this may be 
related to oxidative stress (124). 
1.7.5 D-ROMs test 
The company Diacron has developed a test called the “Diacron reactive oxygen 
metabolites test” (D-ROMs test) in order to assess systemic oxidative stress. The D-
ROMs test is a spectrophotmetric test that measures the total concentration of all 
types of hydroperoxides (ROOH) in biological samples. ROOH are generated in cells 
by oxidative attack of ROS on a number of organic substrates (e.g. carbohydrates, 
lipids, amino acids proteins and nucleotides) (126).  
The D-ROMs test essentially assesses plasma lipid peroxidation. Several publications 
indicate that D-ROM is a valuable biomarker for systemic oxidative stress showing 
higher levels in diseased (39;127;128) than in healthy. 
Table 1.1 below is supplied by the manufacturer. It gives ranges of values as 
determined by the D-ROMs test, and suggests a corresponding oxidative stress level. 
CARR U Oxidative stress level 
< 250 Below normal 
250 - 300 Normal 
300 - 320 Border line 
321 - 340 Low 
341 - 400 Middle 
401 - 500 High 
> 500 Very high 
Table 1.1 Oxidative stress ranges of D-ROMs test 
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1.7.6 8OHdG 
The most common way of assessing DNA ROS damage is by measurement of 
8OHdG (129). 8OHdG is an abundant DNA lesion resulting from ROS. It is the 
result of a hydroxyl radical adduction to a guanine base.  
If not repaired, this modification may result in a carcinogenic DNA mutation, and 
thus 8OHdG may be a biomarker of cancer risk (130;131). Base excision repair 
(BER), nucleotide excision repair and mismatch repair are mechanisms involved in 
the cellular defence against this specific DNA damage. When excised, the oxidized 
guanosine and adjacent nucleosides are being cut out of the DNA strand. The excised 
oxidized guanine nucleoside is subsequently excreted into urine and may be 
measured as 8OHdG. 
The oxidized lesions are stable and fairly water soluble. In order to quantify the 
8OHdG metabolite in other tissue, cleaving by various enzymes is required (130). 
Hydroxylated guanosines in the cellular pool are also excreted in urine and may 
contribute considerably to the measured amounts (132). 
High performance liquid chromatography (HPLC) is the most widely used method 
for measurement of 8OHdG in tissue, lymphocyte and plasma. 
One simple Enzyme-Linked ImmunoSorbent Assay (ELISA) method is commercially 
available from Japan Institute for the Control of Ageing; using a monoclonal 
antibody specific for 8OHdG. Wu et al. (130) describe another ELISA which 
correlate well with the Japanese method. Wu et al. report normal reference values in 
healthy men as 29.6 +/- 24.5 ng/mg creatinine. Cigarette smoking does not appear to 
influence the reference values (130). 
The urinary excretion of 8OHdG is dependent on the rate of ROS damage on DNA in 
tissues. Increased levels of urinary 8OHdG may be a result of increased ROS attack 
or decreased antioxidant protection. Urinary 8OHdG does not directly reflect the 
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steady state level oxidative DNA damage, but it is an indicator of oxidative stress 
(132). 8OHdG from diet is believed not to affect the urinary measures (129). 
There is good reason to believe that oxidative DNA damage, including hydroxylation 
of guanine bases, being the most frequent and most mutagenic lesion in nuclear 
DNA, contributes to the overall cancer risk in humans. Wu et al. (130) report some 
studies showing elevated 8OHdG in tissues and urine indicating increased cancer 
risk. Some connection with hepatocellular carcinoma and elevated 8OHdG due to 
increased iron load in liver cells has been reported. Cancer breast and prostate tissue 
have higher levels of 8OHdG compared to normal tissue (130), though this may be a 
consequence rather than a cause of the disease. 
Quantification of oxidized guanosine, 8OHdG, in tissues or excreted in urine could in 
principle be a good indicator of oxidative stress. However, Halliwell raises a number 
of critical comments to the validity of 8OHdG as a general biomarker of oxidative 
stress: 1) There is no consensus to the true levels in humans, and 2) there are great 
problems of artifactual oxidation in sample preparation. 3) Measuring 8OHdG does 
not take into account the relation between the DNA ROS damage and the rate of 
DNA repair, which may be decisive for the overall disease risk (129;129). 
1.7.7 HEL 
Lipid peroxidation was briefly described in chapter 1.2.3 “Oxidative molecular 
damage”. Some important biomarkers of lipid oxidation are F2-isoprostanes, 
malondialdehyde (MDA), acrolein, HNE and 2 – propenal (12). The lipid oxidative 
damage product examined in this thesis is hexanoyl epsilon lysine (HEL). 
HEL is formed by a reaction between a peroxidated fatty acid and the essential amino 
acid lysine. The name “hexanoyl” indicates that there are six C-atoms in the fatty acid 
part of the HEL molecule. The side group of lysine is negatively charged (basic) at 
physiologic pH. The unstable fatty acid remnant reacts with the epsilon part of the 
lysine residue in a free or protein bound amino acid. HEL is then formed by 
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enzymatic decomposition of the protein. HEL is a stable molecule that is excreted in 
urine (133). 
Based on existing documentation (133;134) and assumptions of the excretion 
pathway, plasma and urine could be good media for determination of the constant 
turnover of HEL in the body. HEL has been measured in some diseases, and 
correlation has been documented between the level of HEL, oxidative damage and 
disease indicators (133-135). 
HEL has been explored as a biomarker of oxidative stress in plants, animals and 
humans (133;136;137). It seems to correlate very well with 8OHdG. It is a promising 
biomarker of oxidative stress, but more and larger studies are required to confirm 
this. 
1.7.8 Ferric reducing ability of plasma (FRAP, modified FRAP) 
The FRAP method is a way to measure the total antioxidant capacity. But in plasma, 
there are endogenous antioxidants that originate from uric acid and proteins. Benzie 
and Strain estimated that uric acid accounts for 60% of FRAP, AA contributes with 
15%, proteins with 10% and alpha-tocopherol and bilirubin with 5% each (138). 
Yeum et al. claim that FRAP and other similar assays mainly measure the 
watersoluble antioxidants (139). The mFRAP method remove uric acid and proteins 
by adding uricase and ethanol before the FRAP analysis is performed. The mFRAP 
result is expected to reflect the levels of dietary antioxidants more closely than FRAP, 
both the water soluble and the lipid soluble fractions. However, antioxidants that act 
by H transfer (thiols and carotenoids) will not be determined in the FRAP assay 
(140). FRAP is analysed using a spectrophotometric method. 
1.8 Compliance biomarkers 
Compliance biomarkers are used in order to verify that the subjects of the study 
actually have ingested and absorbed the intervention foods and supplements. 
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1.8.1 Omega-3 fatty acids 
Red blood cells (RBCs) are easily collected and analysed; and they have a more 
stable day-to-day fatty acid composition than plasma. It has been shown that omega-3 
levels in RBC reflect omega-3 supplementation (141).  
1.8.2 Lycopene 
Plasma lycopene is recognised and well documented as a very good biomarker for 
intake of tomato and tomato products in individuals (142). 
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2. Aims and research questions 
This master thesis addresses oxidative stress biomarkers in a group of PC patients 
compared to an age matched healthy reference population.  
The present work also analyses interim results (27 patients of 102) of a clinical study 
where the overall aim is to investigate whether patients diagnosed with localised PC 
may benefit from a food intervention. The study is the “Prostate cancer, 
phytochemical and PUFA intervention study” (PFPI). The PC patients were given 
tomatoes and other phytochemical rich foods for a period of three weeks and their 
compliance was recorded. The food items were selected based on literature and 
knowledge of antioxidants and phytochemicals in plant foods from research 
conducted by Rune Blomhoff and his research team, and they were believed to give 
an additive or synergistic effect. 
The specific aims of this thesis are: 
 To analyse and compare biological oxidative stress biomarkers in PC patients 
compared to a group of healthy references. 
 To study the compliance to the PC intervention. 
 To analyse and compare the biomarkers of oxidative stress measured in 
plasma and urine samples from the cancer patients, before and after the 
intervention. 
 To analyse and compare the surrogate biomarker of PC, PSA, as measured in 
the PC patients before and after the intervention. 
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3. Materials 
This chapter provides a list of materials and equipment used for sample handling and 
analyses in the laboratories of the University of Oslo. Also purchasing information 
and other details about the intervention food products are listed here. 
3.1 Intervention food items 
Food Manufacturer Location 
Barilla Pasta sauce with basil Ideal Wasa Hamar, Norway 
Dolmio Pasta sauce with garlic Mars Food Melton Mowbray, England 
Dolmio Pasta sauce classico Mars Food Melton Mowbray, England 
Knorr pasta sauce with oregano and 
onion 
Unilever Norge Billingstad, Norway 
Tomato juice 1 L Cadiso Food Frederikssund, Danmark 
Crushed tomatoes, 500g ICA AB Solna, Sweden 
Twinings Java green tea Twinings London, England 
Twinings Earl grey tea Twinings London, England 
Pomegranate juice, 330 mL Tine Oslo, Norway 
Grape juice, 330 mL Tine Oslo, Norway 
Solaray Selenium supplement Nutraceutical Corp for 
Solaray Inc 
Utah, USA 
Soy supplement Natures`s sunshine 
Super soy extra  
Utah, USA 
Omega-3 supplements Nycoplus omega-3 Oslo, Norway 
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3.2 Lycopene content of tomato products 
Manu-
facturer 
Product Packsize Lycopene 
concentration 
mg/100 g 
Daily 
portion 
size 
Lycopene 
content per 
daily portion 
(mg) 
Barilla Pastasauce with basil 400 g glass 16.7 ½ glass 33.4 
Dolmio Pastasauce with garlic 500 g glass 11.6 ½ glass 29.0 
Dolmio Pastasauce classico 500 g glass 14.9 ½ glass 37.2 
Knorr Pastasauce oregano and onion 400 mL glass 15.8 ½ glass 31.6 
Cadiso Tomato juice 1 L carton 11.4 ¼ carton 28.5 
ICA Crushed tomatoes 500 g carton 12.4 ½ carton 31.0 
3.3 Equipment 
CPT  with sodium Citrate BD Vacutainer Franklin Lakes, USA 
Collection tube with Sodium 
Heparin 
BD Vacutainer Franklin Lakes, USA 
Collection tube with K2EDTA BD Vacutainer Franklin Lakes, USA 
Stabilyte blood sampling tubes Biopool (Trinity Biotech plc) Irland 
Urine containers Uriset 24 Sarstedt Nürnberg, Germany 
Urine containers 500 ml  Sarstedt Nürnberg, Germany 
Microtubes 1,5 ml Sarstedt Nürnberg, Germany 
96 well ELISA microplates Greiner BIO-ONE Frichenhausen, Germany 
3.4 Chemicals 
Chemical/compound Manufacturer Location 
Acetic acid Merck Darmstadt, Germany 
Acetone (CH3COCH3) Merck Darmstadt, Germany 
Acetonitrile VWR International Norway 
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Ascorbic acid Sigma-Aldrich Germany 
Argon AGA, 100325 Oslo, Norway 
Ethanol Arcus Kjemi Oslo, Norway 
FeSO4 · 7H2O   Riedel-deHaën AG Seelze, Germany 
FeCl3 · 6H2O BDH Laboratory Supplies Dorset, England 
Hydrocloric acid (HCl) Merck Darmstadt, Germany 
Meta-phosphoric acid (MPA) Riedel de Haën Germany 
2,4,6-tripyrdyl-s-triazine 
(TPTZ) 
Fluka Chemie AG Deisenhofen, Switzerland 
tris[2-carboxyethyl]phosphine 
hydrochloride (TCEP) 
BioChemika Fluka Switzerland 
Trizma buffer Sigma-Aldrich Germany 
Triz buffer Sigma-Aldrich Germany 
DULBECCO´S Phosphate 
Buffered Saline (PBS) 
Sigma-Aldrich Germany 
Urate oxidase Sigma-Aldrich Germany 
NaH2PO4 Sigma-Aldrich Germany 
Dodecyltrimethylammonium 
chloride 
Fluka Chemie Switzerland 
Na2EDTA Sigma-Aldrich Germany 
Milli-Q water Millipore Bedford, MA 
NIST 970 SRM  (National Institute of Standards 
and Technology - Standard 
Reference Materials) 
USA 
 
3.5 Kits 
Kit name Manufacturer Location 
Homocysteine by HPLC-kit, 
Kit no 195-4073 
BIORAD California, USA 
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Diacrons reactive oxygen 
metabolites (D-ROMs test) Kit 
Diacron International Grosetto, Italy 
New 8OHdG Kit Japan Institute for the Control 
of Aging (JaICA) 
Shizuoka, Japan 
HEL Kit Japan Institute for the Control 
of Aging (JaICA) 
Shizuoka, Japan 
3.6 Instruments 
Instrument Manufacturer Location 
Biofuge Fresco Heraeus Instruments Osterode, Germany 
Technican RA 1000 system Technicon Instruments Corp New York, Ny 
L46 Vortex Mixer Labinco the Netherlands 
KS 125 basic microtiter shaker IKA Labortechnik Staufen, Germany 
Termaks Laboratory Incubator Termaks Bergen, Norway 
HP1100 (HPLC) Hewlett Packard USA 
GS-6R Sentrifuge Beckman USA 
Titertec Multiscan PLUS EFLAB Finland 
3.7 Software 
Software package Manufacturer Location 
Microsoft Office XP Microsoft Corporation Redmont, WA 
Reference manager 11 ISI Research soft Carsbad CA 
SPSS 16 for Windows SPSS Inc Chicago, Il 
HP Chemstation version 4 
(HPLC software) 
Hewlett Packard USA 
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4. Subjects and Methods 
4.1 Subjects 
4.1.1 The study population (PC patients) 
The PC patients that constitute the study population were recruited from the 
Norwegian Radium Hospital, Oslo University Hospital in the period from July 2007 
to March 2008 in the PFPI clinical trial.  Eligible patients were enrolled for 
prostatectomy or brachy theraphy (regular therapy) at the hospital. Together with an 
appointment letter for clinical examination, the patients received an invitation letter 
and a letter of informed consent, and were phoned a week later. The inclusion criteria 
included histological diagnosed adenocarcinoma of the prostate gland, and low or 
moderate risk of recurrence (T1c-T3a, PSA < 20 ng/mL or Gleason score of at least 
6) without androgen deprivation therapy. All the patients had expected lifetime > 5 
years and some patients suffered what was described as “not important comorbidity”, 
such as hypertension and skeletal diseases. The inclusion criteria are listed in 
Appendix 3 (143).  
62 patients that met the inclusion criteria were invited to participate, 27 accepted to 
participate and were included and randomized and 26 patients completed the study. 
Figure 4.1 displays inclusion of participants in the PFPI study. Age distribution of 
the study population by five-year age groups is illustrated in Figure 4.2. 
The study was approved by the Regional Ethics Committee for medical Research 
(REK Sør-Øst), and all men gave informed written consent. One participant left the 
study because he was treated prior to original schedule.  
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62 were invited to participate 1.july 2007 – 1.april 2008
27 accepted and were randomized
Control group
n=9
Tomato group
n=9
Coctail group
n=9
n=9
Completed
n=8
Completed
n=9
Completed
1 left because of
rescheduling
 
Figure 4.1 Inclusion and randomisation of participants in the PFPI study, constituting the 
study population 
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Figure 4.2. The age distribution by five-year age group of the study population 
4.1.2 The reference population 
The reference population was drawn from a population of 347 (162 men) apparently 
healthy individuals, random selected by the Statistics Norway, living in Oslo and 
Akershus. For the master thesis, a sub group of 32 were selected based on sex and 
age (male, 40 – 70 years), in order to match the Norwegian age-specific PC incidence 
rates (144). However, five participants had reported chronic inflammatory diseases 
and were left out, leaving 27.  
Figure 4.3 shows the reference population divided by five-year age groups, using the 
same year intervals as for the study population.  
Blood samples were available for all, while urine samples were available for 25 of the 
27. In the reference population, 24 hour urine was collected in a pre-prepared can 
containing 9 ml 20% HCl and 240 mg Vitamin C. 
 
 62 
Age distribution of the reference population
0
1
2
3
4
5
6
7
8
9
10
40-44 45-49 50-54  55-59 60-64 65-69
Age groups
Nu
m
be
r
Reference population
 
Figure 4.3. The age distribution by five-year age group of the reference population. 
4.2 Study design and intervention 
The PFPI study followed a randomized parallel design with a 3 week intervention 
period. The randomization was computer based and carried out by the Registry of 
Clinical Research at the Norwegian Radium Hospital, Oslo University Hospital. The 
subjects were randomized to 1 of 3 groups: one group that consumed a portion of 
various tomato products daily (tomato group, n=9) and one group that consumed 
tomato products and additional foods and supplements (multidiet group, n=9), and a 
control group who would continue their habitual diet (n=9). The intervention was 
given immediately preceding regular therapy. The patients visited the hospital three 
times: visit 1 for inclusion and randomization, visit 2 prior to the intervention period 
and visit 3 the day of regular theraphy. At all visits, overnight fasting blood samples 
and morning urine were collected.  
Before visit 2, the participants filled in a food frequency questionnaire (FFQ). In this 
sheet the patients reported their dietary intake, antropometric measures such as height 
and weight, smoking, alcohol, comorbidity and supplement intake. The questionnaire 
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was filled in at home by the patient and returned in a prepaid envelope to the 
University of Oslo before visit 2. Figure 4.4 gives an overview of the timing, visits 
and data collection. 
Visit 3 Prostatectomy or start of brachy therapy
Visit 1 Blood
Urine
Visit 1, Inclusion and randomization
Visit 2, immediately before the intervention
period, starting 3 weeks before the planned
invasive treatment
5 - 20 weeks break
Shipment of intervention products
time
Visits and timing Data collection
FFQ completed
Visit 2 Blood
Urine
Visit 3 Blood
Urine
3 weeks intervention period
 
Figure 4.4 Timing, visits and data collection of the PFPI study 
Blood and urine samples from visit 2 were missing for 1 subject in the control group 
and one in the tomato group, and visit 2 urine samples were missing for two control 
group patients. 
4.2.1 Intervention foods and supplements 
All patients were asked to continue their habitual diet during the intervention period. 
The control group did not receive any additional food. For the tomato and multidiet 
groups, the intervention products were intended as a supplement to their current diet.  
The tomato group intervention 
The patients randomized to the tomato group were supplied with various tomato 
sauces and canned tomatoes amounting to 200 – 250 grams per day. The tomato 
products had been analysed in our laboratory, and the products with the highest 
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lycopene content were chosen. The tomato group participants received at least 30 mg 
lycopene a day. 
The multidiet group intervention 
The multidiet group received juices, teas and tomato products for 24 days of 
intervention. They also received prepacked supplements from the chemists at the 
Norwegian Radium Hospital, before returning home after visit 1. The foods supplied 
to the multidiet group are listed in Table 4.1. 
Supplement Morning Evening 
Nycoplus omega-3, fish oil 3 × 1000 mg 2 × 1000 mg  
Natures`s sunshine Super soy extra 2 × 40 mg  3 × 40 mg  
Solaray selenium 1 ×100 μg  1 ×100 μg  
Food Daily 
Grape juice 330 ml 
Pomegranate juice 330 ml 
Tomatoes 200 – 250 grams, containing at least 30 mg lycopene 
Green tea 300 ml 
Black tea 300 ml 
Table 4.1 Multidiet group intervention products with daily portions. 
The multidiet group received supplements of selenium, omega-3 fatty acids and soy. 
The daily dose of 200 µg selenium was given as two tablets of organic 1-
selenomethionin. The omega-3 supplement was given as 5 capsules each containing 
1000 mg fish oil, of which 65% is EPA and DHA, adding up to a daily dose of those 
two essential long chained omega-3 fatty acids of 3.25 grams. The patients were also 
supplemented with 200 mg isoflavones as soy bean extract. The daily supplement 
consisted of 5 tablets of  ”Super soy ekstra” from Natures` Sunshine. The 
supplements were divided into morning and evening doses as shown above.  
The multidiet group received the same amount of tomatoes as the tomato group. 
The multidiet group received one cup daily of both Earl Grey green tea and Earl Grey 
black tea. Instructions for the preparation of the teas were as follows: “Heat 3 dl 
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water to the boiling point, pour the water over the tea bag and let it brew for 5 
minutes before removing the tea bag. The tea may then be enjoyed hot or cold and 
sweetened with artificial sweeteners according to taste.” 
Juice from pomegranate and grape were prepared by TINE. The grape juice was 
made of the Merlot grape. The juices were supplied in boxes of 330 ml, constituting 
the daily portion. 
All the intervention products are commercially available, except the pomegranate and 
grape juices which were prepared by Tine for research purposes.  
All the participants were followed up weekly by telephone. Additionally they were 
supplied with telephone numbers and invited to contact the staff at the university or at 
the hospital for further information. 
4.3 Laboratory analyses of biomarkers 
Overnight fasting blood samples were collected by venous puncture in heparin, 
EDTA and citrate CPT (Cell Preparation Tube) tubes. Plasma samples were prepared 
by immediate centrifugation on 1500 g at 4 °C for 10 min. All samples were stored at 
-70 ºC if not immediately analysed. 
For vitamin C analyses, to preserve vitamin C, heparin plasma was immediately 
acidified using an equal volume of 10% meta-phosphoric acid (MPA).  
To determine d-ROMs test, FRAP and mFRAP, heparin plasma was used. EDTA 
plasma was used for determination of lycopene, GSH and cysteine. 
Determination of d-ROMs test, FRAP, mFRAP, lycopene, GSH and cysteine was 
carried out in the Blomhoff laboratory at Department of Nutrition, UiO. For fatty acid 
analysis, RBCs were isolated from citrate CPT tubes. The analysis was performed by 
Vitas laboratories, Oslo. GGT and PSA were assayed by routine laboratory methods 
at the Department of Clinical Chemistry, Norwegian Radium Hospital. 
 66 
HEL, 8OHdG and creatinine were determined in urine. Creatinine was analysed at 
Ullevål Hospital laboratory, while HEL and 8OHdG were tested in the Blomhoff 
laboratory. 
The analyses of the samples from the PC study were performed from August to 
October 2008. The analyses of the reference population samples were performed 
during 2007 and 2008. 
4.3.1 GGT 
GGT were analysed in serum using routine laboratory methods at the clinical 
chemical department at the Norwegian Radium Hospital, Oslo University Hospital. 
This assay is based on VITROS GGT slides and VITROS Chemistry Products 
kalibratorkit 3 on VITROS Chemistry Systems, manufactured by Ortho-Clinical 
Diagnostics, Johnson & Johnson, United Kingdom. 
Briefly, one drop patient serum is evenly distributed on the Vitros Slide. VITROS 
GGT slide is a multi layered analytical element coated on a polyester base. GGT 
present in the sample catalyses the transfer of the gamma-glutamyl portion of L-
gamma-glutamyl-p-nitroanilide to glycylglycine, simultaneously producing p-
nitroaniline. The kinetics of change in reflection densities is measured. Based on 
sequential readings of the slide reflectance at 400 nm over a fixed incubation period, 
the kinetics of change in reflection density is determined. By applying a prepared 
software multipoint calibration model, enzyme activity is calculated, and when a 
calibration has been carried out for each slide-slot, the GGT activity in unknown 
samples can be determined. Adult male reference interval as presented by the 
manufacturer for GGT is 15 – 73 U/L (145). 
4.3.2 Reduced thiols, glutathione and cysteine  
Our analysis method includes the pool of mixed and protein-bound disulfides in 
plasma. This measure is achieved by reduction of disulfides prior to analysis (123). 
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The reduced thiols glutathione (GSH) and cysteine were determined in EDTA plasma 
using the “Homocysteine by HPLC-kit”, according to the manufacturer’s instructions. 
In brief, 50 µL internal standard and 25 µL reduction reagent (trialcylphospide) was 
added to 25 µL plasma. To this solution, 50 µL derivatization reagent (ABD-F) was 
added. The sample was vortex mixed and incubated for 5 minutes at 50 Cº. The 
samples were then refrigerated for 5 minutes, before proteins were precipitated by the 
addition of 50 µL precipitation reagent (tricloroacetic acid). The samples were then 
vortex mixed and centrifuged for 15 min at 4000 g +4 ºC. From the clear supernatant, 
20 µL were used for chromatographic analysis. As mobile phase the “Homocystein 
by HPLC” mobile phase (cat 195-4077) was used at 0.7 ml/min  at 45 ºC with a 
“Homocysteine analytical cartridge” (Catalog no 195-4076, BioRad). For detection, a 
fluorescence detector (FLD) was used (385nm (ex) and 515 nm (em)).  
The healthy population plasma samples for GSH analysis were pre-treated with serine 
borate, in order to avoid GGT to continue its enzymatic activity in vitro (146). The 
plasma samples from the cancer patients were not pre-treated in this way. 
4.3.3 Dehydroascorbic acid: total ascorbic acid 
Total ascorbic acid (TAA) is constituted by AA and DHAA.  
A recently published HPLC method for rapid and accurate determination of the 
vitamin C isoforms DHAA and AA was used (147). In brief, heparin whole blood 
was immediately centrifuged at 2000 g at +4 ºC for 10 min for generation of plasma. 
To preserve vitamin C, the plasma was immediately acidified using an equal volume 
of 10% meta-phosphoric acid (MPA). Ideally, the analysis should be performed 
within 3 months of sample collection to avoid degradation of AA to DHAA.  
The mobile phase consisted of 2% acetonitrile in an aqueous buffer containing 2.5 
mmol/L NaH2PO4, 1.875 mmol/L dodecyltrimethyl ammonium chloride and 1.25 
mmol/L Na2EDTA in milli-q water. The flow rate was 6.0 mL/min. Samples were 
pretreated to reduce DHAA to AA before chromatographic determination. For 
 68 
separation of AA from interfering plasma constituents, a Chromolith Performance 
RP18-e, 4.6x100mm column was used. For detection, a variable wavelength UV 
detector was used at 264 nm. Plasma calibrators quantified against the NIST 970 
SRM (National Institute of Standards and Technology - Standard Reference 
Materials) was used as standards. 
Direct determination of AA 
At time of analysis, the acidified samples were centrifuged at 3000 g and +4 ºC for 15 
min. 100 µL of the clear supernatant was diluted with 400 µL of the aqueous buffer 
in an auto sampler vial. The sample was centrifuged at 3500g for 10 min at +4 ºC and 
5µL was used for chromatographic analysis and determination of AA. 
Reduction of DHAA to determine TAA 
At time of analysis, the acidified samples were centrifuged 3000 g at +4 ºC for 15 
min. 50 µL reduction agent (2.3 mmol/L tris [2-carboxyethyl] phosphine 
hydrochloride (TCEP) in 800 mmol/L trizma buffer, pH 9.0) were added to 100 µL 
of the clear supernatant. After vortex mixing, the sample was incubated at room 
temperature for 7 min for complete reduction of DHAA, before the sample was 
diluted with 350 µL of the aqueous buffer. In this step, DHAA was reduced to AA, 
and the TAA can be determined in the sample. The sample was centrifuged at 3500g 
for 10 min at +4 ºC and 5 µL was used for chromatographic analysis and 
determination of TAA. 
Concentration of DHAA 
The concentration of DHAA was calculated by subtracting the concentration of AA 
from the TAA concentration. TAA and the ratio between DHAA and TAA is used for 
statistical analysis. 
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4.3.4 D-ROMs test 
Diacrons reactive oxygen metabolites (D-ROMs) test was performed according to the 
information provided by the manufacturer (Diacron International, Grosetto, Italy). 
In brief, heparin plasma was diluted in an acidic buffer solution (pH 4.8). Iron present 
in the sample catalysed the breakdown of plasma hydroperoxides to alkoxyl and 
peroxyl radicals, which generate a coloured complex with the chromogen, N, N,-
diethylparaphenylendiamine. The coloured complex was quantified in a photometer 
under the following conditions: filter of 500 nm wavelength, optical path 1 cm, 
temperature 37ºC and kinetic mode. The hydroperoxide concentration was correlated 
with detected colour intensity. The results are denominated in arbitrary units, 
Carratelli Units (CARR U) and 1 CARR U corresponds to 0.08mg H2O2 /100mL 
(126). 
The reaction of this system (simplified): 
R OOH + Fe3+→ R OO• + Fe2+ +H+ 
R OO• + A-NH2 → R-OO− +[A NH2•]+ (coloured) 
Where: 
 R OOH is a generic peroxide.  
 R O• is the alkoxyl radical of a generic peroxide  
 R OO• is the peroxyl radical of a generic peroxide  
 A-NH2  is N,Ndiethyl-para-phenylendiamine (chromogenic substrate).  
 [A-NH2•]+ is the coloured radical cation of the chromogenic substrate  (148). 
4.3.5 The Ferric Reducing Ability of Plasma (FRAP) Assay 
The FRAP assay was used to measure the content of total redox active compounds, 
antioxidants in plasma. The assay is based on the method by Benzie and Strain, 1996. 
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In brief, 300 µL of FRAP reagent (Table 4.2) was added to 10 µL heparin plasma. 
Reducing agents (antioxidants) in the sample reduces the ferric ions to ferrous ions, 
which forms a highly coloured complex with the chromogen,  tripyrdyltriazine TPTZ, 
and an intense blue colour with an absorption maximum of 593nm will appear, 
proportional to the reducing ability of the sample. The reduction takes place at an 
acidic pH. The reaction is non-specific, and any half-reaction which has less positive 
redox potential than the Fe3+/Fe 2+ half reaction will drive the reduction. A Technican 
RA 1000 system was used to determine triplicates of absorption at 600nm. An 
aqueous solution of 500 µmol FeSO4 reagent (Riedel de Haen) was used for 
instrument calibration. 
Reagents Components Volume in FRAP reagent 
Acetate buffer 
300 mmol/l acetate buffer, pH 
3.6  
+ C2H4O2 16 ml buffer solution 
25 ml 
HCl 40 mmol/l 2.4 ml 
FeCl3 20 mmol/l 2.5 ml 
TPTZ solution 250 mg in 5 ml methanol 155 µl 
 
Table 4.2 Frap reagents 
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4.3.6 mFRAP, FRAP after removing uric acid and proteins 
For preparation of samples free of uric acid and proteins, 10 µL uricase (0.1 units/10 
µL) in triz buffer (pH 8.5, 400 mmol/L) were added to 20 µL heparin plasma. After 
incubation for 6 min at room temperature, 80 µL ethanol was added to precipitate 
proteins. The samples were incubated at 4 ºC for 6 min before centrifugation at 
13000g at 4 ºC for 10 min. The clear supernatant was used for FRAP analysis as 
described above. 
4.3.7 Hexanoyl Epsilon Lysine (HEL) in urine 
The amount of HEL in urine was determined by ELISA according to the 
manufacturer’s instructions. The urine samples were sentrifuged at 4000 g and +4 ºC 
for 20 minutes, before 100 µL urine were diluted with 400 µL PBS. 50 µL of the 
diluted urine samples were placed in the wells of the microtiterplate before 50 µL of 
the primary antibody (anti HEL monoclonal antibody) was added. The wells were 
precoated with a hexanoyl-Lys adduct (HEL) from the manufacturer and the HEL in 
the samples would compete with HEL on the well surface for the added anti HEL 
antibody. The plate was sealed and incubated at 250 rpm/min at 4 – 7 ºC for 18-20 
hours. The plate was washed 3 times, removing all HEL in the sample bound to anti 
HEL antibody, before the addition of the secondary antibody. The secondary 
antibody would bind to the anti HEL antibody that was left. The plate was sealed and 
incubated at 500 rpm/min at room temperature for 1 hour. The plate was washed 3 
times to remove unbound secondary antibody, before the addition of 100 µL 
chromogen solute and the plate sealed with light proof aluminium foil and incubated 
at 500 rpm/min at room temperature for 15 minutes. Addition of the chromogen 
results in the development of colour in proportion to the amount of antibody bound to 
the well. The stop solute was added and the absorption was measured at 450 nm 
within 3 minutes. Diluting the wells 1:5 with MilliQ water was necessary to obtain 
absorbance within valid limits. The results were calculated using the standard curve 
as suggested by the manufacturer, with a linear approximation to the logarithmic 
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graph. Standard A and Standard F were removed from the linear curve to get a better 
approximation for the measured values. 
4.3.8 8OHdG in urine 
The amount of 8OHdG in urine was determined by the “New 8-OHdG Check”, 
ELISA Kit according to the manufacturer’s instructions. The kit is utilizing anti 8-
OHdG monoclonal antibody (clone N45.1) which is highly specific for 8-OHdG. 
“New 8-OHdG Check” ELISA is suitable for urine and serum sample from animal 
and human (149). The urine samples were sentrifuged at 4000 g +4 ºC for 20 
minutes, before 100 µL urine were diluted with 300 µL PBS. 50 µL of the diluted 
urine samples were placed in the wells of the microtiterplate and then 50 µL of the 
primary antibody was added. The plate was sealed and left to incubate at 37 ºC for 1 
hour. The plate was emptied and dried with clean cell-tissue and then thoroughly 
washed. The secondary antibody was mixed with secondary antibody buffer and 100 
µL added to the wells. The plate was again sealed and left to incubate at 37 ºC for 1 
hour. The plate was again thoroughly washed. Then 100 µL chromogen solute was 
added, the plate sealed with aluminium foil (light proof) and incubated (shaken at 500 
rpm) at room temperature (20 - 25 ºC) for 15 minutes. The stop solute was added and 
the absorption was measured in the spectrometer at an absorbance of 450 nm. 
Dilution of the samples 1:5 was required for valid measurement. 
4.3.9 Creatinine 
Determination of creatinine was conducted by the clinical chemical department at 
Ullevål University Hospital using the “DRI Creatinine-Detect Test”, according to the 
manufacturer’s instructions. The analysis was performed using an Olympus AU400 
clinical chemistry analyser. BIORAD Liquicheck Urine Chemistry Control 1 lot nr 
62831 with mean of 6.89 mmol/L and Range 5.86 – 7.92 mmol/L was used for 
instrument calibration. 
The method is based on the Jaffe reaction: 
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Creatinine + Picric Acid -> Janovski Complex (Red) 
The Janovski Complex gives a red colour. The colour intensity is directly 
proportional to the creatinine concentration and is measured spectrophotometrically 
at 505nm. 
Urine creatinine is used as a simple measure of concentration, for instance in 
connection with drug abuse testing. It normally varies a lot during the day, greatly 
influenced by e.g. fluid intake. 
Urine male reference values for 24 hours collection are 4 – 17 mmol/d, while the 
reference value for spot urine samples is > 3 mmol/L (150). 
4.3.10 PSA 
PSA were analysed in serum using routine laboratory methods at the clinical 
chemical department at the Norwegian Radium Hospital, Oslo University Hospital, 
using the AutoDELFIA Prostatus™ PSA Free/Total assay (Perkin Elmer, Inc., 
Finland). This assay determines the total and free amounts of human PSA in serum 
using the 1235 AutoDELFIA immunoassay system. Only the total PSA results are 
reported here.  
The assay is a solid phase time-resolved fluoroimmunometric assay based on the 
direct sandwich technique in which three monoclonal antibodies (derived from mice) 
are used (151). In serum, PSA detectable by immunohistochemical methods is 
predominantly found as complexed to alpha-1-antichymotrypsin (PSA-ACT). Small 
amounts of PSA complexed to other serine protease inhibitors are also found. The 
free or uncomplexed fraction of PSA represents 5 – 30 % of the total immuno 
accessible PSA in serum. Total-PSA consists of free PSA and PSA-ACT (152).  
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4.3.11 
4.3.12 
Lycopene 
Lycopene was determined in plasma by HPLC. Proteins were precipitated and 
removed by the addition of a 4.5 volume of isopropanol followed by centrifugation at 
3000 g and 4 °C for 15 minutes. The internal standard astaxanthin was added with the 
isopropanol. 25 µL of the clear supernatant were used for analysis. The mobile 
phases consisted of A: 20 % water and 24 % acetone in ethanol and B: acetone. The 
gradient conditions were as follows: From 2 to 100 % B within 20 minutes, followed 
by 100 % B for 15 minutes. Detection was performed at 453 nm using a variable 
wavelength detector. Plasma calibrators quantified against the NIST 968c SRM 
served as standards. 
Fatty acids in RBC 
Determination of fatty acids in red blood cells was performed at AS Vitas, Oslo. 
100µL of whole blood was prepared with a direct transmethylation and hexan 
extraction of fatty acid methyl esters (FAME) which were subsequently analysed 
with a GC – FID. The results were reported as g fatty acid/100g FAME (Fatty Acid 
Methyl Esters). The reported fatty acids were C20:5, n-3 (EPA); C22:5, n-3 (DPA); 
C22:6, n-3 (DHA) and sum of omega-3 fatty acids. The reported fatty acids, 
including the omega-3 fatty acids, constitute 94 – 97 % of the total fatty acids in the 
sample. 
4.4 Intervention compliance 
When included, and during weekly telephone interviews, the patients were 
encouraged to consume the intervention foods and supplements as prescribed. 
Compliance was recorded in a custom-made questionnaire for daily intake. The 
sheets ”Skjema for registrering av tomatprodukter i intervensjonsperioden” and 
”Skjema for registrering av multi-diett gruppe produkter i intervensjonsperioden” are 
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included in Appendices 6 and 8. The sheet was supplied with a prepaid envelope and 
the patients returned these to the university immediately after the intervention period.  
Lycopene in plasma and fatty acids in red blood cells were analysed as biomarkers of 
compliance. Lycopene in plasma is known to be a very good biomarker for intake of 
tomato products, and omega-3 fatty acids in red blood cells reflect the intake of these 
fatty acids from food and supplements. 
Compliance of the individual participant was evaluated based on the self reported 
sheets, and participants with less than 50% would be classified as non-compliant and 
excluded. 
4.5 Combining biomarkers into indexes 
Measuring a range of biomarkers gives an opportunity to combine them into indexes. 
We suggested that these indexes would reflect the status better that the individual 
biomarkers. The biomarkers were combined into four indexes: 
 Endogenous index (GSH + Cysteine) – these biomarkers may reflect the status 
of the endogenous oxidative stress defence system. 
 Damage index (8OHdG + HEL + d-ROMs test + DHAA:TAA), combining the 
biomarkers that are associated with oxidative stress damage. 
 Antioxidant index (Lycopene + TAA + mFRAP) – these biomarkers measure 
dietary antioxidants. 
 Combined index (DHAA:TAA + GGT + d-ROMs test – GSH – Cysteine). 
The selection of biomarkers for the combined index was based on comparison 
of the study population with the reference population. The selected biomarkers 
were those that turned out significantly different between the two populations 
and GGT which showed a strong trend. The levels of DHAA:TAA, GGT and 
d-ROMs test were higher in the study group than in the reference population, 
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while GSH and Cysteine were lower. Accordingly, we decided to add the first 
three biomarkers and subtract the last two. 
4.5.1 Calculating indexes 
The indexes were calculated in two steps, (1) normalization and (2) adding or 
subtracting selected biomarkers. 
(1) The differences from baseline to after the intervention (Δbiomarker) were 
normalized by the following formula: 
 
(Δbiomarker A (patient a) – group mean Δ biomarkerA 
normalized Δbiomarker A (patient a) 
group standard deviation Δbiomarker A 
(2) The indexes were calculated by addition or subtraction of the normalized 
Δbiomarkers: 
index 1(patient a) =  
normalized Δbiomarker A (patient a) +  
normalized Δbiomarker B (patient a) + … + normalized Δbiomarker N (patient a) 
4.6 Statistical analysis 
Student`s t-test (for normally distributed data) and Mann-Whitney non-parametric 
test (for non-normally distributed data) were performed to analyse the mean and 
median baseline values between the reference population and the PC patients and to 
compare changes that were observed during the intervention period between the 
multidiet, tomato and control groups in the intervention study.  
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Spearman’s and Pearson’s correlation coefficients were used for correlation between 
parameters. 
Visit 2 samples for some of the patients were lacking, as mentioned earlier. Due to 
the small number of participants we used visit 1 samples instead of visit 2 samples as 
baseline values. The statistical analyses were performed with and without these 
values, without substantial differences in the level of statistical significance.  
All statistics were performed using SPSS version 16.0. A p-value below 0.050 was 
considered statistical significant. Results are expressed as mean (range) for normally 
distributed and median (range) for non-normally distributed data. 
4.7 Contribution of the master candidate to the clinical 
study (PFPI) 
Telephone based patient communication including information, asking for 
participation and weekly follow up during the intervention period was carried out by 
the candidate. Coordination and collaboration with the hospital staff and packing and 
shipping the intervention products (juices, teas and tomato products) was handled by 
the candidate.  
Analyses of the biological samples were planned, prepared and coordinated by the 
candidate. HPLC analyses (vitamin C, GSH and cysteine) were carried out by Anette 
Karlsen and observed by the candidate. FRAP, mFRAP and d-ROMs test was carried 
out by the candidate with assistance by Kari Holte. ELISA determination of HEL and 
8OHdG was carried out by the candidate. 
All statistical analyses of all parameters were prepared, executed and interpreted by 
the candidate. 
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5. Results 
5.1 Comparing the study population at baseline to the 
reference population 
Descriptive data of the study population and the reference population were compared 
(Table 5.1). Biomarkers related to oxidative stress and antioxidant status were 
analysed for the two populations and statistical comparisons were performed. From 
the study population, baseline data (from visit 2) were used.  
Table 5.1: Differences between the study population and the reference population 
Parameter 
Reference population 
n = 27a 
Study population 
n = 25 
p 
Descriptive data 
Age b, years 52 (41 - 67) 64 (52 - 74) < 0.001 
BMI a, b, kg/m2 27 (22 - 40) 27 (21 - 36) n.s. 
Nr of smokers 2 3  
Antioxidant biomarkers in plasma 
 
TAA c µmol/L  
n = 27 
52.0 (7.3 – 84.0) 
n = 24 
73.2 (34.5 – 140.1) 
 
< 0.001 
GSH c µmol/L  5.3 (2.8 – 14.10) 4.2 (1.7 – 9.1) 0.009 
FRAP c µmol/L  1297 (793–1604) 1322 (861-1765) 0.383 
Cysteine c µmol/L  293 (226 – 386) 253 (202 – 366) 0.003 
mFRAP c µmol/L  374 (294–443) 421 (297 – 701) 0.003 
Oxidative stress related biomarkers in plasma 
 
DHAA:TAA c ratio  
n=27 
0.071 (0.058 – 0.111) 
n=24 
0.147 (0.025 – 0.280) 
 
< 0.001 
GGT c U/L  25 (12–92) 30 (13 – 145) 0.160 
d-ROMs test c Carr U  166 (105–243) 221 (29 – 295) < 0.001 
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Parameter 
Reference population 
n = 27a 
Study population 
n = 25 
p 
Oxidative damage biomarkers in urine 
 
HEL c nmol/L 
n =25 
127 (43 – 255) 
n=26 
111 (57 – 281) 
 
0.429 
HEL c µmol/mol creatinine 14.6 (3.6 – 34.4) 8.5 (3.2–20.2) 0.004 
8OHdG c, d, ng/mL adjusted 9.8 ( 3.8 – 30.5) 10.0 ( 4.1 – 32.6) 0.865 
8OHdG c, d ng/mmol 
creatinine adjusted 1057 (318 – 2291) 745 (320 –2029) 0.025 
Urine excretion correction factor 
Creatinine c mmol/L 9 (5 – 20) 14 (5 – 22) < 0.001 
a Body weight was self reported in the study population, while it was measured by medical personnel in the 
reference population. 
b Normally distributed parameter, presented as mean (range). Students T-test was used to compare the groups. 
c Non-normally distributed parameter, presented as median (range). Mann-Whitney test was performed to 
compare the groups.  
d Adjustment of 8OHdG: The control urine was calculated against the standardized curve. The control urine 
was then used to calibrate the next kits. ELISA is a semi-quantitative measure, and small variations are 
expected between the kits. Ideally, all the samples would be analysed in one kit, but due to the kit capacity, 
this was not possible. 
5.1.1 Descriptive data 
The mean age of the 27 healthy men and the 25 PC patients included in the analyses 
was 52 years (41 – 67) and 64 years (52 – 74) respectively, thus the PC patients were 
on average 12 years older than the reference population.  
BMI was 27 (22 – 40) in the reference population and 27 (21 – 36) in the study 
population.  
The age distribution in the study population is displayed in Figure 4.2 while the 
reference population is shown in Figure 4.3. There were two smokers in the 
reference population and three smokers in the study population. 
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5.1.2 Antioxidant biomarkers in plasma 
Vitamin C was elevated in the study population compared to the reference population 
(p < 0.001). FRAP was not different between the groups, while mFRAP was higher 
among the cancer patients (p = 0.003). GSH and cysteine were lower in the study 
population compared to the reference population (p = 0.009 and p= 0.003 
respectively). 
5.1.3 Oxidative stress related biomarkers in plasma 
The ratio between oxidised and reduced vitamin C, DHAA:TAA was elevated within 
the study population (p< 0.001) compared to the reference population. There was a 
trend indicating that GGT could be higher in the study population compared to the 
reference population, but this was not statistically significant (p=0.160). D-ROMs test 
was higher in the study population at baseline (p<0.001).  
5.1.4 Oxidative damage biomarkers in urine 
Urinary HEL was not different between the study population and the reference 
population, but when adjusted for creatinine, there appeared to be a significant 
difference (p<0.004) between the groups (Table 5.1). The reference population 
presented higher HEL levels than the study population. Urinary 8-OHdG, when 
adjusted for creatinine, was lower among the study population at baseline than the 
reference population (p<0.025). 
5.1.5 Urine excretion correction factor 
Urinary creatinine was elevated in the study population at baseline compared to the 
reference population (p < 0.001). 
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5.1.6 Correlations between selected biomarkers 
Statistical significant correlations were revealed between some of the biomarkers. 
Figure 5.1 and Table 5.2 illustrate a strong nonlinear correlation between GSH and 
GGT in the study population (p<0.001) and a much weaker trend in the reference 
population (p= 0.087). Figure 5.2 and Table 5.3 display a strong inverse linear 
correlation between d-ROMs test and TAA in the study population (p=0.009) but not 
in the reference population. 
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Figure 5.1 Scatter plot of GGT and GSH in the reference population (left) and the study 
population at baseline (right) 
Spearman’s rho GSH/GGT p 
Reference population -0.34 0.087 
Study population, baseline -0.82 < 0.001 
Table 5.2 Spearman’s rho correlation coefficient of GGT and GSH in the reference population 
and the study population at baseline 
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Figure 5.2 Scatter plot of TAA and d-ROMs test in the reference population (left) and the study 
population at baseline (right) 
Pearson’s correlation D-ROMs test/TAA p 
Reference population -0.096 0.632 
Study population at baseline -0.53 0.009 
Table 5.3: Pearson’s correlation coefficient of TAA and d-ROMs test in the reference 
population and the study population at baseline. 
5.2 Effect of intervention 
5.2.1 Descriptive parameters of the intervention groups 
Table 5.4 shows the descriptive parameters of the intervention groups.  
Parameter Tomato group Control group Multidiet group 
Age b, years  64 (52 - 71) 64 (55 - 69) 65 (54 – 74) 
BMI a, b, kg/m2  25 (21 - 33) 28 (22 - 36) 26 (22 - 29) 
Nr of smokers 1 1 1 
Table 5.4 Descriptive parameters of the intervention groups 
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aBody weight was self reported among the PC patients. 
b Normally distributed parameter, presented as mean (range). Students T-test was used to compare the groups. 
5.2.2 Compliance 
17 patients, 8 in the tomato group and 9 in the multidiet group, completed the tomato 
intervention. The average intervention period lasted for 22.4 days, varying from 21 to 
24 days. The intervention duration would vary to account for weekends, when the 
hospital is closed. The intervention started the day after visit 1 and lasted to include 
the day before treatment. All the patients received tomato products for 26 days of 
intervention. The compliance for the tomato products was 99%, ranging from 93% to 
113%. The reason for compliance above 100% was that some participants consumed 
more than the prescribed daily intake.  
Figure 5.3 shows what the patients preferred. Tomato juice seemed to be the most 
popular product, possibly because it did not require any preparations.  
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Figure 5.3 Consumption of the tomato products. The patients received tomato products enough 
for 26 daily portions. The bars indicate the self reported consumption. 
The multidiet products were consumed by 9 patients. The days of intervention in this 
group varied from 21 to 24 days, with average length of 23 days. Compliance for the 
multidiet products is shown in Table 5.5.  
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Food item Compliance % (range) 
Green tea 96 (73 – 100) 
Black tea 97 (91 – 100) 
Pomegranate juice 98 (91 – 100) 
Grape juice 99 (91 – 100) 
Morning supplements 100 (96 – 100) 
Evening supplements 99 (95 – 100) 
Table 5.5 Consumption compliance of food and supplements in the multidiet group. 
One patient reported problems with dyspepsia which resulted in reduced compliance. 
This patient was familiar with the symptoms. He managed to keep the problem at a 
minimum, and was able to complete the intervention. His digestion problem was 
mainly related to the concentrated juices. 
5.2.3 Compliance biomarkers 
Plasma lycopene and omega-3 fish fatty acids were analysed to verify the self 
reported compliance for tomatoes and omega-3 respectively. These are shown in 
Table 5.6. Plasma concentrations of lycopene increased significantly in the tomato 
group and the multidiet group (p < 0.001 in both groups) as compared to the control 
group. Plasma concentrations of total omega-3 fish fatty acids increased significantly 
in the multidiet group (p < 0.001) as compared to the control group and the tomato 
group.  
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Table 5.6 Compliance biomarkers baseline values and changes during the intervention period. 
Tomato group Control group Multidiet group Difference between 
groups 
Parameter 
n 
Baseline 
 
Difference 
n 
Baseline 
 
Difference 
n 
Baseline 
n 
Difference  
Tomato 
vs 
Control 
Multidiet 
vs 
Control 
Lycopene a, 
µmol/L 
n=7 
0.55 (0.062 – 0.992) 
n=7 
0.41 (0.209 – 1.109) 
n=9 
0.54 (0.21 – 0.82) 
n=9 
-0.10 (-0.55 – 0.05) 
n=9 
0.38 (0.25 – 0.73) 
n=9 
0.37 (0.18 – 1.07) 
< 0.001 < 0.001 
Total n-3 fatty 
acids a, 
mg/100g 
(EPA, DHA, 
DPA) 
n=8 
8.7 (5.7 – 12.8) 
n=8 
-0.1 (-1.9 – 1.1) 
n=9 
9.1 (6.4 – 12.8) 
n=9 
-0.1 (-3.7 – 1.2) 
n=9 
10.5 (8.8 – 12.8) 
n=9 
1.1 (0.9 – 2.3) 
0.963 0.001 
a Non-normally distributed parameter, presented as median (range). Mann-Whitney test was performed to compare the groups.
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5.2.4 Effects of the intervention on the biomarkers of oxidative 
stress 
No effects of the intervention were observed in the biomarkers of antioxidant status 
and oxidative stress. Baseline values and changes after the intervention period for 
plasma and urine measures of antioxidants and oxidative stress status are listed in 
Table 5.7.
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Table 5.7: PC intervention study. Comparison of baseline values and changes during the intervention period. Non-normally distributed parameters, 
presented as median (range). Mann-Whitney test was performed to compare the groups 
Parameter Tomato 
baseline 
Tomato 
difference 
Control 
baseline 
Control 
difference 
Multidiet 
baseline 
Multidiet 
difference 
P  
(difference)  
tomato vs 
control 
P of 
(difference)  
multidiet vs 
control  
Antioxidant biomarkers in plasma 
TAA , µmol/L 
n=7 
71 (57 – 111) 
n=7 
-4 (-36 – 26) 
n=8 
72 (35 – 140) 
n=8 
13 (-94 – 23) 
n=9 
82 (40 – 134) 
n=9 
-3 (-61 – 32) 
0.536 0.277 
GSH , µmol/L 
n=8 
4.5 (1.8 – 6.2) 
n=8 
1.1 (-0.9 – 2.0) 
n=9 
4.0 (3.4 – 9.1) 
n=9 
2.1 (0.1 – 3.3) 
n=8 
4.6 (2.0 – 6.0) 
n=8 
0.9 (-1.34 – 3.9) 
0.167 0.815 
Cysteine , 
µmol/L 
n=8 
246 (213 – 292) 
n=8 
61 (18 – 94) 
n=9 
255 (202 – 366) 
n=9 
63 (24 – 147) 
n=8 
282 (243 – 340) 
n=8 
45 (2 – 92) 
0.606 0.200 
FRAP, µmol/L 
n=8 
1286 (881 – 1675) 
n=8 
37 (-240 – 236) 
n=9 
1343 (966 – 1764) 
n=9 
21 (-158 – 213) 
n=9 
1328 (861 – 1706) 
n=9 
61 ( -193 – 259) 
0.888 1.000 
mFRAP, µmol/L 
n=8 
427 (355 – 701) 
n=8 
-92 (-266 – 39) 
n=9 
417 (297 – 508) 
n=9 
-31 (-126 – 186) 
n=9 
407 (362 – 557) 
n=9 
-65 ( -111 – 48) 
0.167 0.387 
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Parameter Tomato 
baseline 
Tomato 
difference 
Control 
baseline 
Control 
difference 
Multidiet 
baseline 
Multidiet 
difference 
P  
(difference)  
tomato vs 
control 
P of 
(difference)  
multidiet vs 
control  
Oxidative stress related biomarkers in plasma 
DHAA:TAA  
ratio 
n=7 
0.132 (0.079 – 
0.201) 
n=7 
-0.031 (-0.119– 
0.033) 
n=8 
0.172(0.025–0.233) 
n=8 
-0.068(-0.228– 
0.010) 
n=9 
0.172 (0.058–
0.280) 
n=9 
-0.060 (-0.183– 
0.014) 
0.189 0.963 
d-ROMs test, 
Carr U 
n=6 
248 (189 – 295) 
n=6 
-1 (-83 – 19) 
n=9 
225 (163 – 246) 
n=9 
1 (-18 – 28) 
n=9 
207 (137 – 253) 
n=9 
12 (-26 – 27) 
0.776 0.340 
GGT  U/L 
n=7 
23 (17 – 105) 
n=7 
2 (0 – 9) 
n=9 
27 (13 – 46) 
n=9 
0 (-3 – 3) 
n=9 
33 (20 – 145) 
n=9 
0 (-48 – 39) 
0.071 0.931 
Oxidative damage biomarkers in urine 
U-HEL  nmol/L 
n=8 
105 (57 – 124) 
n=8 
21 (-66 – 52) 
n=9 
128 (59 – 281) 
n=9 
-5 (-138 – 146) 
n=9 
150 (87 – 212) 
n=9 
17 (-55 – 87) 
0.815 0.863 
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Parameter Tomato 
baseline 
Tomato 
difference 
Control 
baseline 
Control 
difference 
Multidiet 
baseline 
Multidiet 
difference 
P  
(difference)  
tomato vs 
control 
P of 
(difference)  
multidiet vs 
control  
Oxidative damage biomarkers in urine 
U-HEL 
µmol/mol 
creatinine 
n=8 
7.0 (3.8 – 17.0) 
n=8 
2.7 ( -1.8 – 11.4) 
n=9 
8.3 (3.2 – 20.2) 
n=9 
2.2 (-1.6 – 20.7) 
n=9 
9.1 (7.2 – 11.9) 
n=9 
2.9 (-5.4 – 24.2) 
1.000 0.730 
U-8OHdG a 
ng/mL adjusted 
n=8 
8.4 (4.1 – 32.6) 
n=8 
0.13 (-5.7 – 6.6) 
n=9 
11.9 (6.3 – 27.1) 
n=9 
-1.3 (-11.0 – 12.8) 
n=9 
12.4 (4.1 – 26.1) 
n=9 
-2.1 (-8.1 – 3.5) 
0.200 
 
0.863 
 
U-8OHdG a 
ng/mmol 
creatinine, 
adjusted 
n=8 
761 (385 – 1906) 
n=8 
184 (-621 – 341) 
n=9 
752 (481 – 2029) 
n=9 
17 (-595 – 1574) 
n=9 
739 (320 – 1194) 
n=9 
65 (-190 – 396) 
0.888 0.796 
Urine excretion correction factor 
Creatinine 
mmol/L 
n=8 
13.8 (4.5 – 17.1) 
n=8 
-1.0 (-8.1 – 1.7) 
n=9 
13.9 (8.6 – 20.4) 
n=9 
-2.1 (-10.4 – 3.2) 
n=9 
15.0(9.6 – 22.0) 
n=9 
-3.6 (-12.8 – 12.2) 
0.423 0.489 
a Adjustment of 8-OHdG: The control urine was calculated against the standardized curve. The control urine was then used to calibrate the next kits. ELISA is a semi-
quantitative method and small variations are expected between the kits. Ideally, all the samples would be analysed in one kit, but due to the kit capacity, this was not 
possible.  
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5.2.5 Combining the measures: indexes 
To evaluate a combination of the biomarkers four indexes were calculated. These 
were Endogenous index, Damage index, Antioxidant index and Combined index. 
Explanation of the index calculation was presented in chapter 4.5 
The results and analyses of the indexes are listed in Appendix 9. No effects of the 
intervention were observed in the combined biomarkers. 
5.2.6 Prostate Specific Antigene 
Plasma PSA was determined immediately before and after the intervention period and 
the results are presented in Table 5.8. Although not significant when compared to the 
control group (p = 0.071), a strong trend of PSA reduction was observed for the 
tomato group. There was also a trend for lower increase of PSA within the multidiet 
group (p= 0.114) when compared to the control group.  
Table 5.9 shows that PSA developed significantly different between the intervention 
groups (tomato and multidiet groups, added together) and the control group 
(p=0.045). 
Figure 5.4 presents bar charts of the PSA and lycopene differences over the three 
week’s intervention. No controls presented PSA decline, while in the multidiet group 
four of nine experienced a reduction of PSA. In the tomato group three of seven 
showed total PSA reduction.
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Table 5.8: PC patient intervention study, plasma PSA before and after the intervention period. Non-normally distributed parameter, presented as 
median (range). Mann-Whitney test was performed to compare the differences between the groups. The baseline values did not differ statistically significant 
between the groups. 
Tomato groupa Tomato groupa Control groupa Control groupa 
Multidiet 
groupa 
Multidiet 
groupa 
P of difference 
Parameter 
n 
Baseline 
n 
Difference 
n 
Baseline 
n 
Difference 
n 
Baseline 
n 
Difference 
Tomato 
vs 
Control 
Multidiet 
vs 
Control 
P-PSA, µg/L 
n=7  
8.1 (4.7 – 19.0) 
n=7  
0.0 (-3.0 – 2.7) 
n=8 
7.7 (3.9 – 16.0) 
n=8 
1.3 (0.0 – 3.0) 
n=9 
10 (4.9 – 20.6) 
n=9 
0 (-2.4 – 2.2) 
0.072 0.114 
a Non-normally distributed parameter, presented as median (range). Mann-Whitney test was performed to compare the groups.  
Table 5.9 PC patient intervention study. Plasma PSA before and after the intervention period for the patients receiving tomatoes (The tomato and multidiet 
groups are added). Non-normally distributed parameter, presented as median (range). Mann-Whitney test was performed to compare the differences between 
the groups. A p-value below 0.050 is considered statistically significant. The baseline values did not differ statistically significant between the groups. 
Intervention groups Intervention groups Control group Control group 
Parameter n 
Baseline 
n 
Difference 
n 
Baseline 
n 
Difference 
P of difference 
Intervention vs Control 
 
P-PSA, µg/L 
n=16 
9.2 (4.7 – 20.6) 
n=16 
0.0 (-3.0 – 2.7) 
n=8 
7.7 (3.9 – 16.0) 
n=8 
1.3 (0.0 – 3.0) 
 
0.045 
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Figure 5.4 Bar charts showing the ΔPSA µg/L and Δlycopene µmol/L for each patient as a 
result of the 3 week intervention 
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6. General discussion 
The health benefits of fruits and vegetables are widely believed to be due partly to 
the presence of phytochemicals. Several of these compounds act as antioxidants 
that may prevent oxidative damage to cells and molecules, thereby reducing 
oxidative stress in the human body. 
Recent literature indicates that oxidative stress appears in connection with cancer, 
but it is not clear whether patients that contract cancer are characterised by initially 
lower antioxidant status and higher oxidative stress than others or whether the 
disease increases oxidative stress and diminishes antioxidant defence. 
The following hypothesis is proposed: 
PC is associated with elevated oxidative stress and with diminished antioxidant 
defences. This hypothesis leads to the following predictions, which can be 
examined in the light of our results:  
 
1. Higher oxidative stress and lower antioxidant status in the study population 
compared to the healthy reference population 
2. The food and supplement intervention will increase antioxidant status 
3. The food and supplement intervention will decrease markers of oxidative stress 
4. The food and supplement intervention will decrease markers of disease (PSA) 
5. Additive or synergistic interaction between the foods and supplements in the 
multidiet intervention will impose stronger effects on antioxidant status, 
markers of oxidative stress, and PSA than tomato intervention alone. 
 
The foods and supplements used in the intervention were selected because of their 
proposed PC preventive properties. Furthermore, the selected plant foods contain 
 94 
high amounts of phytochemicals with strong antioxidant properties, and the 
tomato products were selected based on laboratory determination of lycopene 
contents. 
The present results are interim, based on 27 patients, while the study was designed 
for 102 patients. The results must be interpreted accordingly. 
6.1 COMPARING THE CANCER PATIENTS TO THE 
REFERENCE POPULATION 
6.1.1 Populations and selection 
The mean BMI (Body Mass Index) and the number of smokers were similar 
between the populations. However, the mean age of the study population was 12 
years higher than the mean age of the reference population and the age distribution 
was slightly different as shown in Figures 4.2 and 4.3.  
According to “The free radical theory of ageing”, introduced in 1954 by Denham 
Harman (153), the continuous metabolism of O2 in mitochondria produces free 
radicals (or rather ROS) that accumulate and cause damage, and this constitutes 
the inborn ageing process (153). Several hypotheses trying to elucidate the 
mechanisms of ageing have been proposed, but none are generally accepted. 
However, according to Voss and Sies (154), oxidative damage products such as 
lipid, protein and DNA damage may increase with age, while the plasma thiol 
concentration may decline and the amount of oxidized cysteine (cystine) and GSH 
(GSSG) may increase (154). Therefore it is possible that the age difference 
between the PC population and the healthy reference population could affect our 
results. 
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6.1.2 Antioxidants 
Vitamin C and mFRAP 
Plasma TAA and mFRAP medians were significantly higher (p<0.001 and 
p=0.003) in the study population (73 µmol/L and 421 µmol/L) than the reference 
population (52 µmol/L and 374 µmol/L). These results were in contrast to our 
prediction of diminished antioxidant defences in the study population compared to 
the reference population. 
There are a number of case-control studies that have compared AA between 
cancer patients and healthy controls, and the majority of these do not support our 
findings. Surapaneni et al. (155) found a decrease in erythrocyte AA in a group of 
PC patients and suggested that this was due to higher antioxidant turnover. 
Furthermore, lower plasma vitamin C status has been measured in other groups of 
cancer patients compared to age and sex matched controls (39;156). 
Differences were probably not due to sample preparation, storage and analysis as 
these were performed according to the description in Chapter 4.3.3, and the 
samples from the two populations were treated equally. With respect to TAA 
determination, due to acidification and excellent treatment before storage, higher 
levels of TAA may be measured using this method than other methods (157). 
One plausible reason for the higher plasma TAA and mFRAP in the study 
population than the reference population is increased health awareness as a 
consequence of the serious cancer diagnosis. This may entail higher intake of 
fruits and vegetables among the cancer patients than the reference population. 
Furthermore, the subgroup of cancer patients who enrol for a study like this may 
also be interested in healthy eating and they may believe that this could improve 
their prognosis to a higher degree than those who decline to participate. 
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Ten PC patients presented plasma TTA above 80 µmol/L and this is higher than 
one would expect from food sources alone (43), indicating that these patients used 
vitamin supplements. Although the patients were requested not to use dietary 
supplements when enrolling in the study, they probably did.  
Thus, the differences between the groups may be due to a combination of vitamin 
supplements and increased fruits and vegetable intake. 
GSH and cysteine 
The GSH and cysteine medians were significantly lower in the study population 
than in the reference population, (p=0.009) and (p=0.003) respectively, and this 
was in line with our predictions. 
According to the antioxidant network hypothesis (45), this result could be 
anticipated in a condition of oxidative stress: Low levels of GSH could indicate 
elevated turnover of GSH. High GSH turnover would require increased GSH 
synthesis. Cysteine is a precursor of GSH, and high GSH synthesis may lead to 
cysteine depletion which eventually would impair GSH synthesis. 
The sample collection was, however, performed differently between the groups. 
The samples from the reference population had serine borate added to inhibit GGT 
enzymatic activity in vitro, while the samples from the study population did not. 
GGT enzymatic activity in the sample during storage and analysis may break 
down GSH and thus affect the results. Possible interaction between GGT and GSH 
in vitro may be illustrated by the strong non-linear correlation detected between 
GSH and GGT in the study population. There was a trend towards a similar 
correlation in the reference population, but this was not significant. See Figure 5.1 
and Table 5.2.  
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Serine borate would, however, not influence levels of cysteine. The significant 
lower plasma cysteine in the study population compared to the reference 
population could be due to oxidative stress in the study population, and suggest 
that the difference in GSH may also be explained by a condition of oxidative 
stress.  
There are limited data comparing GSH in cancer patients to healthy controls; 
however, the few data that are available do not suppoort our findings. In an 
unpublished work of Sakhi et al. (39), employing the same method for total GSH 
determination treated with serine borate, no significant difference in total GSH 
was observed between a group of untreated head and neck squamous cell 
carcinoma (HNSCC) patients compared to controls. 
6.1.3 Oxidative stress biomarkers in plasma 
In spite of extensive research in the area of oxidative stress biomarkers, there is 
currently no generally agreed gold standard of oxidative stress determination, and 
the levels of various biomarkers diverge and are not easily reproduced between 
laboratories and methods of analysis (158). A challenge for oxidative stress 
measurement is artifactual oxidation occurring at any stage during sample 
collection, storage, thawing and analysis and this may introduce substantial error 
(12). Of the analysis techniques employed, HPLC is a quantitative determination 
method while ELISA is semi quantitative. According to Yoshida et al. (159), 
results with the commercial ELISA kit for 8OHdG determination correlate well 
with a HPLC assay and could be used to compare groups, but other reports have 
concluded differently (159). 
As both plasma and urine may reflect the whole body exposure, these may not be 
relevant media for determination of oxidative stress in PC. Assuming that the 
prostate weighs 30 grams in a male body of 70 kg, the oxidative stress produced 
 98 
by the prostate gland alone probably would not be measurable in the systemic 
body fluids (H.E.Poulsen and A.R.Collins, manuscript in preparation). 
The various biomarkers are influenced by factors such as nutrition, lifestyle, 
genetic background and smoking implying that large numbers of individuals are 
needed to get significant differences in studies monitoring the change of 
biomarkers with age (154). 
GGT 
Although not significant, a trend indicating higher GGT levels in plasma of the 
study population than the reference population was observed. As higher GGT in 
the study population may indicate a state of oxidative stress in this group, this 
corresponded to our predictions. 
Higher GGT may be caused by biliary tract disease, liver disease or excessive 
alcohol consumption. However, the median values in the groups were 25 U/L 
(reference population) and 30 U/L (study population) respectively, and virtually 
all values were within normal range, suggesting that the difference may not be due 
to liver disease or alcohol intake. 
The NORIP  reference value (150) upper limit steps from 80 U/L before to 115 
U/L after 40 years of age, suggesting an expected increase of GGT with age. Thus, 
the difference between the groups may be due to the observed age differences 
between the two populations.  
Our findings are supported in the comprehensive literature of GGT and cancer. By 
data from cell and animal studies, increased GGT activity is associated with 
enhanced tumour growth (160) and tumour oxidative stress resistance (161). GGT 
has been shown to be up-regulated under conditions of oxidative stress in 
carcinoma cells (162). 
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Strasak et al. (163) demonstrated stronger associations between GGT and cancer 
risk in participants below 65 years. Several prospective studies have demonstrated 
GGT as predictor of cancer risk and mortality of various sites (163-166). 
D-ROMs test 
Our study population had significantly higher median d-ROMs results (221 Carr 
U) than the median of the reference population (166 Carr U), indicating higher 
oxidative stress among the cancer patients which is in line with our predicted 
expectations (p<0.001). 
However, measures made by our laboratory seem to give lower values than the 
Diacron scale. According to the scale none of our cancer patients expressed 
oxidative stress. Our values do correspond to the results of Sakhi et al. (39), a 
project run in the same laboratory, where controls versus pre-radiotherapy 
HNSCC d-ROMs levels were 155.9 Carr U and 219.6 Carr U respectively.  
A possible explanation to the low levels could be the Norwegian eating pattern 
being different from the Italian. But in a Norwegian study of preeclampsia, d-
ROM median values in healthy pregnant women were 457 (411–514) Carr U and 
in preeclampsia 550 (425–586) Carr U (127).  
According to Diacron, the d-ROMs test results are not influenced by age (126), 
suggesting that the measured difference between the two populations could be due 
to oxidative stress. Supporting the hypothesis of an antioxidant defence network, a 
strong inverse linear correlation between the d-ROMs test and TAA was observed 
in the study population though not in the reference population. See Figure 5.2 and 
Table 5.3. An interpretation of this observation could be that the cancer patients 
were experiencing oxidative stress and in this group AA was utilised to reduce 
oxidative stress implying that those with high TAA were able to scavenge more 
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ROS than those with lower TAA levels, while in the reference population the AA 
turnover was lower and therefore not correlated to d-ROMs test. 
Disregarding the measurement scale, a difference in d-ROM values between the 
study population and the reference population has been confirmed in other cancer 
populations. Already mentioned were the HNSCC results, and in a group of lung 
cancer patients the levels of oxidative stress were higher than those in normal 
subjects (555.3+/-30.35 Carr U versus 360.1+/-17.46 Carr U) (128).  
DHAA:TAA 
The study population had significantly higher ratio of DHAA:TAA than the 
reference population (p<0.001). Applying the antioxidant network theory, high 
DHAA:TAA could indicate that oxidation of vitamin C occurs at a high rate and 
that the thiol cycle and other reducing agents would be unable to recycle DHAA 
back to AA at a corresponding rate. The high ratio of DHAA:TAA suggested a 
condition of systemic oxidative stress, which could be connected to the PC 
diagnosis, hence this results confirmed our prediction. 
Lykkesfeldt found higher plasma DHAA in smokers than in non-smokers (167) 
and in a study of untreated chronic leukaemia patients, a significantly higher 
plasma DHAA:TAA ratio was measured compared to a control group (168). 
6.1.4 Oxidative damage biomarkers in urine 
The daily excretion of the biomarkers in urine is stable, but the urine biomarker 
concentration varies with urine volume, depending on fluid intake and fluid 
excretion. Urinary creatinine was determined to enable correction of the day-to-
day variation in urine volume. 
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Creatinine 
The creatinine levels were significantly higher (p<0.001) in the study group than 
in the reference population. Elevated creatinine is, however, not associated with 
PC and the difference was unexpected.  
The urine samples from the cancer patients, both baseline and after the 
intervention, were collected and treated similarly, and analysed in the same batch 
at Ullevål University Hospital.  
Urine retention was an exclusion criterion among the cancer patients, and could 
thus be ruled out as a cause of this difference. 
Creatinine is supposed to be stable but may vary with meat intake, heavy exercise, 
urine volume and muscle mass; however such factors should cause effects in both 
groups, and were not expected to give significant differences between the groups. 
The reference population had 24- hours’ urine samples collected, while the study 
population collected overnight urine. This could explain the differences. 
8OHdG  
Before correcting for creatinine, 8OHdG was not different between the study 
population and the reference population, but the creatinine adjusted 8OHdG in 
urine was significantly higher in the reference population than in the study 
population. We predicted elevated oxidative stress among the cancer patients. As 
increased level of 8OHdG is an indicator of oxidative stress, we would expect 
higher levels of 8OHdG among the cancer patients than the reference population. 
Possible explanations of the results could be methodological or due to the 
differences in creatinine concentration between the population. Difference in urine 
collection procedures may influence the creatinine concentration and hence the 
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creatinine adjusted 8OHdG. Furthermore, we experienced large 8OHdG inter-
assay variation, and the control sample was used as calibrators.  
There are limited data comparing urinary 8OHdG between cancer patients and 
healthy controls; but, the few that are available do not support our findings. 
Miyake et al. (169) showed significantly higher levels of urinary 
8OHdG/creatinine in PC patients compared to age matched healthy controls. 
Miyake also demonstrated that age was significantly associated with urinary 
8OHdG/creatinine among the cancer patients but not to disease stage or PSA 
(169). Chiou et al. (170)  measured higher 8OHdG in 16 PC patients than in 
healthy controls, but no information about clinical stage or PSA was presented 
(170). 
HEL 
There was no difference in urinary HEL between the two populations, however 
creatinine adjusted HEL in urine was significantly higher in the reference 
population than in the study population. This was not in line with our prediction. 
Rather, being an indicator of oxidative stress, HEL levels were expected to be 
higher in the study group.  
The unpredicted results may be explained by weaknesses in the analysis method 
and by differences in urinary creatinine concentration. 
There are to date no published data concerning urinary HEL determination in 
human cancer patients. 
Our results revealed no correlation between HEL and 8OHdG. This was in 
contrast to Kato et al. (133) who, using a chromatographic analysis method, 
documented correlation between HEL and 8OHdG in human urine of healthy 
 103 
subjects. Furthermore, Kato et al. detected higher urinary HEL levels in diabetic 
subjects than in controls (133). 
6.1.5 Summing up the comparison 
There are indications of differences in levels of cysteine, DHAA:TAA, d-ROMs 
test, GGT (although not significant) and mFRAP between the populations. 
Cysteine was significantly lower in the study population than in the reference 
population, while DHAA:TAA, d-ROM, GGT and mFRAP were higher in the 
study population than in the reference population. 
Relating these results to the antioxidant network hypothesis, a condition of 
oxidative stress could imply increased turnover of substrates in the AA cycle and 
the thiol cycle. Low cysteine, high DHAA:TAA ratio and high d-ROMs test in the 
study population support the antioxidant network hypothesis and are consistent 
with our predictions of higher oxidative stress and lower antioxidant status in the 
PC patients compared to the reference population. 
6.2 EFFECT OF INTERVENTION 
6.2.1 COMPLIANCE 
The compliance of the intervention was excellent. The average tomato product 
consumption was 99% while the average intake of the multidiet products varied 
from 96% (green tea) to 100% (morning supplements). The reported compliance 
was confirmed by the two biomarkers: lycopene and omega-3 fatty acids.  
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The patients that accepted to join the study were very motivated, and few and mild 
adverse symptoms were reported. These were mainly related to dyspepsia. None 
of the patients reported adverse symptoms from the tomato products.  
The patients in the multidiet group received grape juice, pomegranate juice, green 
tea and black tea, and in volume this added up to 1.3 litres of liquid per day. In 
addition to the liquid they would eat or drink 200 – 250 grams of tomato products 
daily and take capsules of omega-3, selenium and soy. As anticipated, the 
intervention foods did replace some of their usual intake of coffee and juice, and 
increased the pasta and tomato sauce intake for dinner. The patients in the 
multidiet group were generally happy to finish off after the three weeks of 
intervention.  
Our observation of high tolerability was in contrast to Jatoi et al. (171) (Table 6.1) 
who reported gastrointestinal side effects and 43 of 46 discontinued the treatment. 
However, this intervention, conducted by the Mayo Clinic, lasted for years rather 
than months, and the disease stage was advanced (171). 
6.2.2 BIOMARKERS OF OXIDATIVE STRESS 
Comparing each of the two intervention groups to the control group revealed no 
significant effect of the intervention in any of the measured oxidative stress related 
biomarkers. 
An effect from the tomato intervention to dampen oxidative stress and increase 
antioxidant status was expected according to our predictions. Furthermore, the 
multidiet combining tomatoes, grape juice, pomegranate juice, green tea, black tea, 
omega-3 PUFA, soy and selenium was proposed to induce additive or synergistic 
effects on the biomarkers.  
Several factors may moderate our results: 
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 Results could be hampered by weaknesses in the sample handling and 
analysis methods.  
 Oxidative stress biomarkers originating from the prostate gland may not be 
measurable in systemic fluids.  
 The intervention study was designed to include 102 participants. This 
interim analysis, based on 27 patients may not display effects due to large 
inter individual variation in response.  
 Three week’s intervention may be too short duration for detectable 
differences to appear. 
 Our hypothesis and predictions may be wrong. 
The food items and supplements selected for the intervention have indicated 
possible preventive effects on PC in epidemiologic studies. In cell culture and 
animal studies they have shown anti-carcinogenic effects. Selenium is essential in 
the endogenous antioxidant defence system. Apart from selenium and omega-3 
PUFAs the food items are also known for their high contents of polyphenols and 
antioxidants. 
The literature indicates that tomatoes, grape juice, pomegranate juice and 
selenium, omega-3 PUFA and soy supplements inhibit oxidative damage and 
support the endogenous antioxidant defence system and potentially reduce 
oxidative damage. Chen et al. (50) documented reduction in leukocyte 8OHdG 
after three weeks intake of tomato-based pasta dishes in 32 PC patients (50). 
Similar effects on lymphocyte DNA damage in healthy volunteers from tomato 
extract and purified lycopene supplementation have been confirmed by others 
(172;173). Daily consumption of grape juice for 8 weeks reduced DNA damage in 
peripheral lymphocytes significantly (174). Selenium supplementation inhibited 
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8OHdG formation in rodents exposed to various carcinogens (175). Conflicting 
results were reported about effect of pomegranate juice on GSH in rodents 
(176;177). In a group of elderly subjects, supplementation with either fish or soy 
oil was related to an increase of Cu/Zn SOD activity and an increase in GSH 
plasma levels (178). Studies of animal models of skin, lung, colon, liver and 
pancreatic cancer have consistently indicated that tea and tea polyphenols 
administration inhibit carcinogen-induced increases of DNA damage (179). 
6.2.3 PSA EFFECTS 
There was a trend indicating an effect on PSA in the tomato (n = 7, p = 0.072) and 
multidiet groups (n = 9, p = 0.114) compared to the control group (n = 8), as 
shown in Table 5.8. The intervention effect on PSA in the joint tomato and 
multidiet groups (n = 16) compared to the control group (n = 8) was statistically 
significant (p = 0.045) as displayed in Table 5.9. Figure 5.4 displays bar charts of 
all the patients’ change in PSA over the three weeks intervention. Potential non-
responders, i.e. individuals experiencing increased PSA values, are found in both 
intervention groups: four of nine in the multidiet group and two of seven in the 
tomato group were non-responding. 
A reduction of PSA in both intervention groups compared to the controls was 
anticipated according to our predictions.  
Tomato effect on PSA 
Few participants may be one reason for non-statistically significant results from 
the tomato intervention. Stronger effects may be detected when including more 
patients in the study. 
Non-responding could be due to one or more of several mechanisms; here are 
suggested three possibilities: 1) Diet gene interaction (see section 1.6); for 
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example Goodman et al. (112) documented that the Arg/Arg genotype of the 
XRCC1 gene combined with high lycopene and carotenoid plasma values could 
reduce PC risk dramatically (112). Other somatic genes may also interact with 
effective chemopreventive substances. 2) There may be subtypes of PC resistant to 
the tomato intervention. 3) Lycopene absorption seems to vary between 
individuals (180) and could be a reason for non-responding. However; in the 
current study there was no sign of correspondence between PSA non-responding 
and plasma lycopene levels as illustrated in Figure 5.4. 
There is a large and growing literature about the effect of tomato products and 
other bioactive food constituents on diagnosed PC, and many clinical interventions 
are in progress. Of the clinical trials that have been published, few are randomized, 
blinded or controlled. The sample sizes of the studies are small, the duration is 
short and the clinical stages vary from a high-risk population to aggressive 
terminal disease. 
Tomato extracts containing high amounts of lycopene are available as Lyc-O-
Mato® capsules from LycoRed, an Israel based company. In addition to lycopene, 
Lyc-O-Mato contains various carotenoids, tocopherols, phospholipids and 
phytosterols (57;181). Four of the six trials in Table 6.1 administrated extract 
capsules instead of whole food. Knowing the recent literature on adverse outcomes 
from antioxidant supplementation, there may be a good reason to be sceptical to 
many kinds of antioxidant supplements (109). However, there may be a difference 
between tomato extract capsules and synthetically manufactured lycopene. 
Table 6.1 lists six recent clinical trials testing tomato or tomato extracts in PC 
patients. All six trials used PSA as a surrogate biomarker of PC progression. PSA 
was demonstrated as a valid biomarker linked to tumour response (182). Of the six 
trials, two addressed localised PC or stage t1-t2. Kucuk et al. (57) used Lyc-O-
Mato, while Bowen et al. (50) used tomato sauce, both supplementing a daily 
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lycopene dose of 30 mg. The Lyc-O-Mato trial (57) had the same number of 
participants as the current study, duration of three weeks and did show a trend of 
difference in PSA between the groups, but not significant. Comparing our current 
significant result with the result of Kucuk et al. (50) may indicate that the tomato 
extract is less effective than whole food tomato products with known high 
lycopene content. The tomato sauce study (50) included 32 in intervention, only 7 
controls and lasted for 3 weeks. The PSA reduction was highly significant. In a 
high-risk group of 81 Afro-Caribbean men supplied with Lyc-O-Mato capsules 
PSA decreased the first month but increased subsequently (183).  
Clark et al. (184) treated a group of 36 advanced stage PC patients with Lyc-O-
Mato for one year, with doses ranging from 15 to 120 mg lycopene. The 
conclusion from this trial was that there was no PSA response (184). 
An Indian trial (185) treated 20 patients with androgen independent and metastatic 
disease. Administrating “Lycored softule” capsules of 10 mg lycopene daily, for 
three months Ansari and Gupta found one complete response, ie normalization of 
PSA and 16 patients had partial response or no progression (185).  
Jatoi et al. (171) at the Mayo Clinic treated 46 androgen-independent and 
metastatic cases with tomato based juice and sauce and only one patient 
experienced a transient decline in PSA. 
Multidiet effect on PSA 
According to our predictions, the multidiet effect on PSA, where the patients 
received multidiet in addition to tomato products, would be greater than the effect 
of tomato products alone; however, no additional effect was seen. 
Few participants and short duration may limit our findings. If there is an effect, the 
statistical power will be strengthened by including more participants. Potential 
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non-responding weakened the effect. Possible explanations for non-responding in 
the tomato group may be relevant also for the multidiet participants. 
 In addition to antioxidant effects, the many dietary constituents of the multidiet 
intervention food products that have been proposed to dampen PC may activate 
signalling pathways that lead to activation of response elements, upregulating gene 
transcription and translation of proteins involved in e.g. cell cycle control, 
apoptosis, cell growth and expression of detoxifying enzymes (89;90;186-189). 
Such adaptive effects may require more than three weeks of exposure to be fully 
effective. Thus, the intervention duration may have been too short to detect 
additional or synergistic effects on PSA in the multidiet group compared to PSA in 
the tomato group.  
One study has shown promising effects of pomegranate juice on human PC (94); 
however this intervention lasted for 24 months and more. A few animal studies are 
published that show synergistic effects on cancer from combinations of foods. 
Zhou et al. (190) reported a synergistic effect on mice tumour weight and 
metastasis with a combination of soy concentrate and tea (190). A study in 
transgenic mice (191) showed a synergistic inhibitory effect of dietary vitamin E 
succinate, selenium, and lycopene on PC incidence. Clinical trials have yet to 
confirm this effect (191). A study of Chinese men (192) suggested that habitual tea 
drinking and intakes of vegetables and fruits rich in lycopene could lead to a 
reduced risk of PC. Interaction analysis showed that the protective effect from tea 
and lycopene consumption was synergistic (p<0.01). Together they had a stronger 
preventive effect than either component taken separately (192).
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Table 6.1 Human PC tomato/lycopene trials 
Food/extract 
from food 
Lycopene 
dose 
Study design Duration Disease stage Number of Patients Results Pub 
year 
Article/main 
author 
Tomato 
oleoresin extract 
30 mg Randomized 
Controlled 
Trial 
3 weeks T1 and T2, 
scheduled for 
prostatectomy 
15 intervention 
11 controls 
PSA increase in control 
group, decrease in 
intervention gr. P=0.25 
2002 Omer Kucuk, 
Hawaii, USA 
(57) 
Tomato sauce 30 mg Clinical 
intervention 
3 weeks Localised 
prostate adeno 
carcinoma 
32 on intervention 
7 random controls 
Average serum-PSA 
decreased p<0.001 
2002 Phyllis Bowen, 
Illinois, USA 
(50) 
Lycored 
softules 
10 mg Clinical 
intervention 
3 months Androgen 
independent  
metast. disease 
20 patients, no 
controls 
CR: 1 patient, PR: 6 
patients, SD: 10 patients, 
Progr: 3 patientsb 
2004 Ansari and 
Gupta, India 
(185) 
Lyc-O-Mato 15 – 90 mg Clinical 
intervention 
1 year PSA increase 
after local 
therapy 
36 on intervention 
No control group 
No PSA responsea 
 
2006 Clark, North 
Carolina, USA 
(184) 
Lyc-O-Mato 
and/or 
multivitamin 
30 mg Phase 1 
clinical trial 
4 months High risk group 81 Afro-Caribbean 
men, randomized in 
3 groups 
PSA decreased first month 
but was back to baseline 
after 4 mnths. No diff 
between the groups 
2007 Bunker, 
Pittsburgh, USA 
(183) 
Tomato paste or 
tomato juice 
30 mg Phase 2 study 3-4 rep. 
cycl. of 28 
days 
Androgen 
independent 
46 patients on 
intervention, no 
control group 
PSA declined in one patienta 2007 Jatoi, Mayo 
Clinic, USA 
(171) 
aResponse defined as 50% decrease in serum PSA from baseline.  
bA complete response (CR) was defined as a normalization of PSA (<4 ng/mL) and the disappearance of any sign of disease for at least 8 weeks. A partial 
response (PR) was defined as a >50% decrease in PSA level for at least 8 weeks associated with improvement (or no worsening) in ECOG PS and relief of bone 
pain if present. Stable disease (SD) was defined as a <50% decrease or <25% increase in the PSA level associated with no worsening of ECOG PS and/or bone 
pain for at least 8 weeks. (ECOG PS, Eastern Cooperative Oncology Group performance status.)
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7. Conclusion 
The hypothesis and predictions proposed in the discussion were not completely 
acknowledged in the present data; however predictions one and four may be 
confirmed. Furthermore, the effects were based on 27 patients and need to be 
reiterated upon the completion of the PFPI project when 102 patients have been 
included. 
We have demonstrated that PC patients may have higher oxidative stress levels and 
diminished antioxidant defences than healthy controls. We suggest that the observed 
elevated biomarkers of oxidative stress may represent a plausible elevation of 
oxidative stress associated with PC. However, we cannot rule out the possibility that 
the age difference between the two groups influences our findings. 
We observed that compliance and tolerability of the intervention diet were excellent, 
and only one patient reported dyspepsia but still managed to complete the 
intervention. 
We suggest that tomato products or multidiet foods may be favourable for patients 
with localised PC. Increase in PSA accompanies the development of PC into an 
aggressive and terminal disease. Our findings indicate that the PSA increase may be 
delayed when PC patients eat tomato products with a high content of lycopene, 
possibly in combination with the other multidiet nutrients, over a three week period. 
Our material did not reveal an additional effect from other phytochemicals than those 
found in tomatoes on PSA in localised PC, but the effect on PSA in the multidiet 
group was comparable to the effect in the tomato group.  
We did not document any relationship between biomarkers of oxidative stress, 
antioxidant status and PSA development during the three weeks of intervention, but 
further research is required. 
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8. Future perspectives 
PFPI has planned to include 102 patients in the study. Availability of these data may 
enable stronger PSA effects to be seen, from both intervention groups. Synergistic 
effect in the multidiet group may be revealed. Further PFPI analyses will examine 
oxidative stress in prostate tissue rather than in systemic body fluids as urine and 
blood. 
Administration of dietary compounds, with minimal side effects, to prevent, slow or 
reverse cancer, could be attractive as a supplement to the conventional PC treatment. 
Tomato products or lycopene may be a prosperous candidate; however several issues 
need further evaluation before it may be recommended in clinic: 
1) The effects on PSA may be transient and therefore longer lasting interventions are 
required.  
2) Whether synthetic lycopene, Lyc-O-Mato capsules or whole food heat prepared 
tomatoes will give optimal effect needs to be addressed. If equally effective, it may 
be favourable to administrate capsules in a long term intervention.  
3) Optimal lycopene dosage must be investigated.  
4) Compliance for longer lasting intervention should be examined. It may be difficult 
to recruit participants to adhere to the multidiet intervention for a longer period. 
However, if the patients experience good effect and minimal adverse reactions, they 
may comply for a longer duration.  
5) In which clinical stage such a treatment could be effective must be further studied.  
6) Tomato products in combination with other foods could give valuable synergistic 
effects.  
7) In future, an individual multidiet of foods or supplements may be tailored 
according to patient response and genetic factors. 
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DNA microarray is a technique for gene expression profiling that has become the 
standard research tool for high-throughput examination of genome wide expression 
changes in PC. In the search for better understanding of the disease pathogenesis and 
progression, the DNA microarray makes it possible to find and classify PC 
progression signatures like dysregulated genes, from cancer cells of groups of 
individuals (193). Investigating PC tissue using micro array analyses may reveal the 
genetic differences between cancers that do respond and do not respond to food and 
supplement treatment. However, such high-throughput techniques generate large 
amounts of data. Thus a great challenge in future research will be the interpretation 
and statistical analysis of information.  
Systems biology will definitely influence the future research in nutrition and cancer. 
Building comprehensive models and quantifying all components and interactions 
probably give a better understanding of the antioxidant network and other cellular 
processes that may be of importance in this field. 
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Appendices 
Appendix 1 Invitation letter, PFPI study 
Invitasjon til å delta i en vitenskapelig studie hvor vi undersøker om en 
kostintervensjon påvirker markører i blod, urin og prostata 
Du mottar dette brevet i forbindelse med din behandling ved Rikshospitalet-
Radiumhospitalet helseforetak (RR). 
I samarbeid med Professor Rune Blomhoff ved Avdeling for Ernæringsvitenskap ved 
Universitetet i Oslo (UiO) ønsker vi å undersøke hvordan et endret kosthold over en kortere 
periode før strålebehandling eller prostatektomi påvirker kreftceller i vev, og hvilke 
forandringer dette fører til i blod og urin. De ulike matvarene er utvalgt med bakgrunn i at 
det er rapportert lavere forekomst av prostatakreft i befolkningsgrupper som spiser mye av 
disse. 
Deltagelsen i undersøkelsen er frivillig, og dersom du ønsker å delta, vil dette på ingen 
måte påvirke den behandlingen du får i forbindelse med din sykdom. 
Vedlagt finner du to eksemplarer av samtykkeinformasjonen ” Forespørsel om å delta i en 
vitenskapelig undersøkelse”. Denne informasjonen inneholder relevant informasjon om 
undersøkelsen, og vi vil be deg lese gjennom denne. Dersom du ønsker å delta er det viktig 
at du signerer et eksemplar av denne, og tar den med til den avtalte undersøkelsen.  
I forbindelse med undersøkelsen ønsker vi også å kartlegge dine kostvaner. Dette gjør vi 
med et spørreskjema, ”Hva spiser du?”. Dette skjemaet vil du få ved først undersøkelse, og 
du kan ta det med hjem for utfylling før du returnerer det til oss per post. Du kan gjerne ta 
kontakt med oss underveis dersom du har spørsmål om utfylling av skjemaet. 
Din deltagelse i denne undersøkelsen vil ikke forandre på behandlingen du skal få, men 
vil gi oss verdifull kunnskap til bruk i behandling av prostatakreft i fremtiden. 
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En forskningssykepleier vil i løpet av noen dager ta kontakt med deg for å gi eventuell 
utfyllende informasjon om undersøkelsen. 
MVH 
_____________   ______________ 
Rune Blomhoff   Sigbjørn Smeland  
Professor, UiO   Klinikksjef, RR  
 
Ta gjerne kontakt med oss dersom du har spørsmål om undersøkelsen! 
Anette Karlsen, prosjektkoordinator, UiO  Tlf 22 85 15 24  
Prosjekttelefon: 41 00 56 89  
e-mail: anette.karlsen@medisin.uio      
Silje Kjelling, forskningssykepleier   Tlf 22 93 58 02  
e-mail: silje.kjelling@radiumhospitalet.no 
Wolfgang Lilleby, behandlende lege   Tlf 22 93 41 89  
e-mail: wolfgang.lilleby@medisin.uio.no 
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Appendix 2 Letter of informed consent, PFPI study 
Forespørsel om å delta i en vitenskapelig undersøkelse  
Prostatakreft, fytokjemikalier og flerumettede fettsyrer (PUFA) 
intervensjonsstudie (PFPI) 
Vi vil gjerne spørre deg om du kunne tenke deg å delta i en undersøkelse av hvordan et 
kostforsøk (bestående av tomatprodukter, grønn og sort te, granateple- og druejuice, soya, 
selen og omega-3-fettsyrer) før strålebehandling eller prostatektomi påvirker kreftceller i 
vev, og hvilke forandringer dette fører til i blod og urin.  
En slik undersøkelse krever at vi må ta ekstra prostatabiopsi, samt ekstra blod- og urinprøver 
av deg.  
Hensikten med undersøkelsen  
Ved Rikshospitalet-Radiumhospitalet prøver vi å forbedre våre behandlingsmetoder. 
Det er holdepukter for at prostatakreft kan påvirkes av ulike typer matvarer. Kostforsøk er en 
eksperimentell behandlingsform, hvor vi ønsker å undersøke hvorvidt enkelte pasienter kan 
ha nytte av en slik behandling. Overvåkning av kreftceller før og etter en forsøksperiode kan 
gi oss verdifull informasjon om kreftceller er følsomme for spesielle matvarer. De ulike 
matvarer er utvalgt med bakgrunn i observerte gunstige sammenhenger mellom inntak og 
forekomst av prostatakreft som har blitt rapportert.  
Undersøkelsen gjøres i samarbeid med Professor Rune Blomhoff ved Avdeling for 
Ernæringsvitenskap ved Universitetet i Oslo. 
Prøvetaking 
Til undersøkelsen tas det blodprøver og urinprøver. I tillegg ønsker vi å ta to ekstra 
vevsprøver fra prostata. Den første vil tas før kostforsøket av urolog, utført med 
lokalbedøvelse på samme måte som da diagnosen ble stilt. Etter forsøket, og i forbindelse 
med innvendig strålebehandling eller operasjon taes den andre biopsien mens du ligger i 
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narkose. Av og til kan man få lettere ubehag ved prøvetaking fra prostata og observere noe 
blodtilblanding i avføring, urin og sæd. Det foreligger en viss risiko for urinveisinfeksjon, 
som reduseres ved bruk av forbyggende antibiotika. Vi vil også se hvordan nivået av  
forskjellige varianter av gener involvert i oksidativt stress kan si noe om hvordan de 
markører vi måler påvirkes av undersøkelsen. 
I tillegg til å avgi prøver til undersøkelsen, vil vi ved to tidspunkter (ved oppstart og ved ett 
års oppfølging) be deg fylle ut et skjema for registrering av dine kostvaner. Skjemaet kan du 
fylle ut hjemme og returnere til oss i ferdig frankert returkonvolutt. 
Forsikring 
Du er forsikret i henhold til reglene i Lov om produktansvar.  
Registrering av data og opprettelse av forskningsbiobank 
I forbindelse med undersøkelsen vil det bli laget et eget register for å kunne analysere 
resultatene på en rask og effektiv måte. Alle data vil bli behandlet konfidensielt, og under 
databehandlingen og publikasjon er alle data avidentifisert. Selve registeret vil bli slettet når 
studien er gjennomført og resultatene publisert, og senest i 2022. 
Opplysninger i din journal er underlagt taushetsplikt i henhold til Helsepersonelloven, og 
bare de som trenger å se den i forbindelse med undersøkelse og behandling har tilgang til 
den. Statens legemiddelverk og annen kontrollmyndighet har også rett til innsyn i din journal 
ved deltagelse i denne type undersøkelse, dette for å sikre undersøkelsens kvalitet. Disse 
kontrollmyndighetene er også pålagt taushetsplikt. 
Det biologiske materialet (blod-, urin-, vevsprøvene) vil bli oppbevart i en biobank ved 
Avdeling for Ernæringsvitenskap ved Universitetet i Oslo. Ansvarlig for biobanken er 
Professor Gunnar Nicolaysen ved Institutt for Medisinske Basalfag ved det Medisinske 
Fakultet, Universitetet i Oslo. Biobanken er godkjent av Sosial og Helsedirektoratet.  
Du kan på et hvert tidspunkt før offentliggjøring av resultatene i internasjonale tidsskrift 
trekke tilbake ditt samtykke til at prøvene blir brukt til forskningsformål, og prøver og 
eventuelle personopplysninger vil da bli destruert og slettet  
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Studien er tilrådt av Regional komite for forskningsetikk (REK Sør) og av statens 
legemiddelverk (SLV). 
Begrensninger ved deltagelse 
Det er enkelte legemidler du ikke kan bruke mens du deltar i studien. Derfor er det viktig at 
du forteller legen hvilke legemidler du bruker eller ønsker å bruke. Det gjelder også 
legemidler som du får kjøpt uten resept og naturmedisiner.  
Forsøksperioden 
Ved innledning av studien vil deltagerne fordeles mellom tre grupper: tomatgruppe, multi-
diett gruppe og kontrollgruppe. Hvilke gruppe du tildeles til er tilfeldig. Dersom du tildeles 
til tomatgruppen vil du bli bedt om å innta en rekke produkter som inneholder tomat over en 
periode av tre uker. For variasjonenes skyld er det ulike produkter å velge mellom. Dersom 
du tildeles til multi-diett gruppen vil du bli bedt om å innta tomatprodukter, grønn og sort te, 
granateple- og druejuice og kosttilskudd som inneholder omega-3 fettsyrer (PUFA), selen og 
soya over 3 uker. Også her kan du velge mellom ulike tomatprodukter. Dersom du tildeles til 
kontrollgruppen vil du kunne fortsette ditt vanlige kosthold. 
Varighet av forsøket og oppfølging 
Forsøksperioden varer i tre uker. Det er viktig for oss at du i denne perioden 
(..forsøksperioden) gjør ditt beste for å spise de matvarene du har fått utdelt, i den mengden 
vi ber deg om. For at vi skal registrere hvilke matvarer du har spist vil vi derfor be deg om å 
registrere dette i et skjema som du får hos oss. 
I løpet av perioden vil du ukentlig bli kontaktet per telefon for å registrere eventuelle 
komplikasjoner som følge av forsøket. Dersom eventuelle komplikasjoner skulle oppstå, ber 
vi om at du rapporterer disse tilbake til oss i disse intervjuene, eller ved å kontakte 
ansvarshavende lege ved kontaktinformasjon som er gitt nedenfor. 
Frivillighet 
Din deltagelse i denne undersøkelsen vil ikke forandre på behandlingen du skal få, men vil 
gi oss verdifull kunnskap til bruk i behandling av prostatakreft i fremtiden. Din deltagelse er 
frivillig og du kan trekke deg når som helst. Dersom du ikke vil delta i studien eller trekker 
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deg, får du den behandlingen og oppfølgingen som vanligvis blir gitt til pasienter med 
samme diagnose som deg. Det er viktig at du informerer legen om du ønsker å avbryte 
behandlingen.   
Vi gjør oppmerksom på at TINE BA bidrar med kr 400.000 til dekning av enkelte 
analysekostnader i tillegg til juicen som inngår i forsøket. Det økonomiske bidraget fra TINE 
utgjør kun en meget liten del av totalkostnadene til studien, og vil ikke påvirke den 
vitenskapelige publiseringen av resultatene fra studien. 
Samtykke 
Jeg samtykker i å delta i undersøkelsen. Jeg har mottatt en egen signert kopi av 
pasientinformasjonen. 
 ________________________________________________________________________ 
  (Dato)            Navn (blokkbokstaver)   (Underskrift) 
 
Behandlende leges underskrift 
Dersom du har spørsmål om behandlingen eller undersøkelse mens du er hjemme ta 
kontakt med ansvarlige lege for undersøkelsen ved Radiumhospitalet: 
Dr. med. Wolfgang Lilleby                 Tlf. 22 93 41 89 
Forskningsykepleier Guro Lindviksmoen Tlf. 22 93 57 74 
Dersom du har spørsmål om kostforsøket, prosjektkoordinator Anette Karlsen: 
Prosjektkoordinator Anette Karlsen   Tlf: 22 85 15 24  
Prosjektmedarbeider Magnhild Kverneland  Tlf: 41 00 56 89 
Dersom du har spørsmål om kostskjemaet, ta kontakt med ansvarlig for registrering 
av kosthold ved Avdeling for Ernæringsvitenskap: 
Stipendiat Monica Carlsen    Tlf. 22 85 15 13 
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Appendix 3 Inclusion criteria for the PFPI study 
Pasient seleksjon og inklusjonskriteria 
 
1. Histologisk bekreftet adenocarsinom 
2. pN0/NXM0 (TNM/UICC 2002) og minst en negativ prognosefaktor for HDR-BT 
eller lav-intermediær risiko profil ved radikal prostatektomi. 
3. PSA< 20 ng/mL+(Gleason score=>6) eller T1c- T3a, prostatavolum < 60mL 
4. Performance status 0-1 
5. Normale hvite og trombosytter, Hb >11g/dl 
6. Ikke tidligere endokrin behandling 
7. Livsforventing > 5 år 
8. Ikke betydningsfull komorbiditet (hjerte-kar, KOLS, insulinkrevende diabetes 
mellitus, vaskulitt, inflammatorisk tarmsykdom etc. som kan ha innflytelse på 
livskvalitet eller strålebehandling. 
9. Ikke urinretensjon, inkontinens, IPPS score <12 (gjelder HDR-BT pasienter). 
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Appendix 4 Informasjon til alle 
Kjære deltager i undersøkelsen kostintervensjon ved prostatakreft 
I denne forsendelsen har du fått de produkter du skal spise og drikke i forsøksperioden. 
I tillegg har du fått to beholdere i klar plast. Disse er til urinprøver. Når du skal til 
blodprøvetakingen før du starter forsøket og etter at forsøket er avsluttet, samler du 
morgenurinen på beholderen og tar denne med til laboratoriet på Radiumhospitalet.  
Lykke til! 
Dersom du har spørsmål om undersøkelsen kan du når som helst kontakte oss. 
 
Anette Karlsen, prosjektkoordinator, UiO  Tlf 22 85 15 24  
e-mail: anette.karlsen@medisin.uio 
 
Magnhild Kverneland, prosjektmedarbeider   
Prosjekttelefon:      Tlf  41 00 56 89  
e-mail: magnhild.kverneland@studmed.uio.no 
               
Guro Lindviksmoen, forskningssykepleier  Tlf 22 93 57 74 
e-mail:guro.lindviksmoen@radiumhospitalet.no 
 
Wolfgang Lilleby, behandlende lege   Tlf 22 93 40 00  
e-mail: wolfgang.lilleby@medisin.uio.no 
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Appendix 5 Informasjon til tomatgruppen 
 
Du har fått følgende tomatprodukter for forsøksperioden: 
1 glass Barillo Pastasaus basilikum   
1 glass Dolmio Pastasaus hvitløk   
1 glass Dolmio pastasaus classico 
1 glass Knorr pastasaus oregano og løk    
3 kartonger Cadisco tomatjuice 1 L    
3 kartonger ICA tomater hakket    
 
Du kan selv velge hvilke tomatprodukt du vil spise eller drikke en porsjon av hver dag.  
 
Tomatproduktene skal konsumeres over hele forsøksperioden. Det er viktig at du spiser 
omtrent den rette daglige porsjonen av det enkelte produkt, som angitt nedenfor: 
 
Barilla  Pastasaus med basilikum  ½ glass/porsjon 
Dolmio Pastasaus hvitløk   ½ glass/ porsjon 
Dolmio Pastasaus classico   ½ glass/ porsjon 
Knorr  Pastasaus med oregano og løk ½ glass/ porsjon 
Cadisco Tomatjuice    ¼ kartong (2,5 dL)/ porsjon 
ICA  Tomater, hakket   ½ kartong/ porsjon 
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Vedlagt finner du noen forslag til anvendelse av de enkelte produktene. 
Det er viktig at du så langt det er mulig ikke gjør store endringer i kostholdet i løpet av 
forsøksperioden. Det vil si at den ekstra porsjonen med tomat så langt det er mulig skal 
komme utenom det du spiser til vanlig. 
Når du har spist ellet drukket den angitte porsjonen, krysser du dette av i skjemaet du har fått 
vedlagt ”Skjema for registrering av produkter i forsøksperioden: Tomatgruppe”. 
Dersom du for eksempel har spist ½ glass Barilla Pastasaus med basilikum dag 1, 5/3-2007, 
og drukket ¼ kartong (2,5 dL) Cadisco tomatjuice dag 2, 6/3-2007, krysser du av som vist: 
 Merke 
navn 
Produkt Inntak Dag 1 Dag 2 Dag 3 
 Dato: 5/3 6/3  
Barilla Pastasaus med 
basilikum 
½ glass ×   
Dolmio Pastasaus extra 
hvitløk 
½ glass    
Dolmio Pastasaus classico ½ glass    
Knorr Pastasaus med 
oregano og løk 
½ glass    
Cadisc
o 
Tomatjuice ¼ 
kartong 
 ×  
A
v 
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ss
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ne
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 d
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en
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ig
 ICA Tomater, hakket ½ 
kartong 
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Du har fått utdelt nok produkter til 25 dager. Dette er fordi det for noen kan være 
vanskelig å få til nøyaktig 21 dager. Dersom du har produkter til over etter avsluttet 
forsøksperiode, trenger du ikke levere disse tilbake til oss. 
 
Skjemaet ”Skjema for registrering av produkter i forsøksperioden: Tomat gruppe” 
som du har fylt ut underveis, sender du til oss i den frankerte konvolutten du har fått 
tilsendt, etter forsøksperioden. 
Lykke til! 
 
Dersom du har spørsmål om undersøkelsen kan du når som helst kontakte oss. 
 
Anette Karlsen, prosjektkoordinator, UiO  Tlf 22 85 15 24  
e-mail: anette.karlsen@medisin.uio 
 
Magnhild Kverneland, prosjektmedarbeider  Tlf 41 00 56 89  
e-mail: magnhild.kverneland@studmed.uio.no 
               
Guro Lindviksmoen, forskningssykepleier  Tlf 22 93 57 74 
e-mail:guro.lindviksmoen@radiumhospitalet.no 
 
Wolfgang Lilleby, behandlende lege   Tlf 22 93 40 00  
e-mail: wolfgang.lilleby@medisin.uio.no 
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Appendix 6 Skjema for registrering av daglig inntak for 
tomatgruppen 
Skjema for registrering av produkter i forsøksperioden:  
Tomatgruppe    ID nr:  
Skjemaet er på 4 sider (1 side for hver uke).  
For hver dag skal du velge en porsjon av tomatprodukt gitt i tabellen. Den mengden 
som tilsvarere en porsjon som du skal spise eller drikke er gitt under inntak (kolonne 
4). Det du spiser daglig skal registreres i tabellene. 
Da det for mange kan være vanskelig å få til nøyaktig 21 dager, går skjemaene til 
og med 28 dager. 
Skjemaene sendes inn til oss i den frankerte konvolutten du har fått tilsendt, etter 
forsøksperiodens slutt. 
 
Uke 1: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 1 Dag 2 Dag 3 Dag 4 Dag 5 Dag 6 Dag 7 
D o:at        
Barilla Pastasaus med 
basilikum 
½ g  lass        
Dolmio Pastasaus extra 
hvitløk 
½ g  lass        
Dolmio Pastasaus Classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ g  lass        
Cadisco Tomatjuice ¼ 
kartong 
       
A
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a
n
 
d
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g
e
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ICA Tomater, hakket ½ 
kartong 
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Uke 2: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 8 Dag 9 Dag 10 Dag 11 Dag 12 Dag 13 Dag 14 
Dat  o:       
Barilla Pastasaus med 
basilikum 
½ gl  a ss        
Dolmio Pastasaus extra 
hvitløk 
½ gl  a ss        
Dolmio Pastasaus Classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ gl  a ss        
Cadisc
o 
Tomatjuice ¼ 
kartong 
       
A
v
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e
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o
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k
t
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n
e
 
k
a
n
 
d
u
 
v
e
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g
e
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n
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r
s
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n
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ICA Tomater, hakket ½ 
kartong 
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Uke 3: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 15 Dag 16 Dag 17 Dag 18 Dag 19 Dag 20 Dag 21 
Dat  o:       
Barilla Pastasaus med 
basilikum 
½ gl  a ss        
Dolmio Pastasaus extra 
hvitløk 
½ gl  a ss        
Dolmio Pastasaus Classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ gl  a ss        
Cadisc
o 
Tomatjuice ¼ 
kartong 
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n
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ICA Tomater, hakket ½ 
kartong 
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Uke 4: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 22 Dag 23 Dag 24 Dag 25 Dag 26 Dag 27 Dag 28 
Dat  o:       
Barilla Pastasaus med 
basilikum 
½ gl  a ss        
Dolmio Pastasaus extra 
hvitløk 
½ gl  a ss        
Dolmio Pastasaus Classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ gl  a ss        
Cadisc
o 
Tomatjuice ¼ 
kartong 
       
A
v
 
d
i
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e
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o
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k
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e
 
k
a
n
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ICA Tomater, hakket ½ 
kartong 
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Dersom du har spørsmål underveis, må du gjerne ta konatkt med oss. 
 
Lykke til!! 
 
Anette Karlsen, prosjektkoordinator, UiO  Tlf 22 85 15 24  
e-mail: anette.karlsen@medisin.uio 
 
Magnhild Kverneland, prosjektmedarbeider  Tlf 41 00 56 89  
e-mail: magnhild.kverneland@studmed.uio.no 
               
Guro Lindviksmoen, forskningssykepleier  Tlf 22 93 57 74 
e-mail:guro.lindviksmoen@radiumhospitalet.no 
 
Wolfgang Lilleby, behandlende lege   Tlf 22 93 40 00  
e-mail: wolfgang.lilleby@medisin.uio.no 
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Appendix 7 Informasjon til multi-diett gruppe 
Tomatprodukter 
Du har fått følgende tomatprodukter for forsøksperioden: 
1 glass Barillo Pastasaus basilikum   
1 glass Dolmio Pastasaus hvitløk   
1 glass Dolmio pastasaus classico 
1 glass Knorr pastasaus oregano og løk    
3 kartonger Cadisco tomatjuice 1 L    
3 kartonger ICA tomater hakket  
 
Andre matvarer du også har fått: 
1 pakke Twinings Java grønn te 
1 pakke Twinings Earl grey te 
24 kartonger a 330 mL granateplejuice 
24 kartonger a 330 mL druejuice 
 
I tilegg til disse matvarene kommer kosttilskuddene som du har fått ved apoteket på 
radiumhospitalet. 
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Tomatprodukter 
 
Du kan selv velge hvilke tomatprodukt du vil spise eller drikke en porsjon av hver dag. 
Tomatproduktene skal konsumeres over hele forsøksperioden. Det er viktig at du spiser 
omtrent den rette daglige porsjonen av det enkelte produkt, som angitt nedenfor: 
Barilla  Pastasaus med basilikum  ½ glass/porsjon 
Dolmio Pastasaus hvitløk   ½ glass/ porsjon 
Dolmio Pastasaus classico   ½ glass/ porsjon 
Knorr  Pastasaus med oregano og løk ½ glass/ porsjon 
Cadisco Tomatjuice    ¼ kartong (2,5 dL)/ porsjon 
ICA  Tomater, hakket   ½ kartong/ porsjon 
 
Vedlagt finner du noen forslag til anvendelse av de enkelte produktene. 
 
Det er viktig at du så langt det er mulig ikke gjør store endringer i kostholdet i løpet av 
forsøksperioden. Det vil si at den ekstra porsjonen med tomat så langt det er mulig skal 
komme utenom det du spiser til vanlig. 
 
Når du har spist ellet drukket den angitte porsjonen, krysser du dette av i skjemaet du har fått 
vedlagt ”Skjema for registrering av produkter i forsøksperioden: multi-diettgruppe”. 
 
Dersom du for eksempel har spist ½ glass Barilla Pastasaus med basilikum dag 1, 5/3-2007, 
og drukket ¼ kartong (2,5 dL) Cadisco tomatjuice dag 2, 6/3-2007, krysser du av som vist: 
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 Merke 
navn 
Produkt Inntak Dag 1 Dag 2 Dag 3 
 Dato: 5/3 6/3  
Barilla Pastasaus med 
basilikum 
½ glass ×   
Dolmio Pastasaus extra 
hvitløk 
½ glass    
Dolmio Pastasaus classico ½ glass    
Knorr Pastasaus med 
oregano og løk 
½ glass    
Cadisc
o 
Tomatjuice ¼ 
kartong 
 ×  
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 ICA Tomater, hakket ½ 
kartong 
   
 
Andre matvarer 
Ved siden av tomatproduktene skal du også drikke grønn og sort te, granateplejuice og 
druejuice. Av disse produktene skal du innta samme mengde av alle produktene hver dag 
i hele forsøksperioden. Dette vil si: 
1 kopp grønn te daglig (Twinings green tea) 
1 kopp sort te daglig (Twinings earl grey) 
1 kartong granateplejuice daglig (0,33 L) 
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1 kartong druejuice daglig (0,33 L) 
 
Grønn og sort te tilberedes på følgende måte: Bruk et krus som rommer tre dL. Varm 3 
dL vann til kokepunktet. Hell vannet over teposen og la dette trekke i 5 minutter før du tar ut 
teposen. Teen kan deretter drikkes varm, eller avkjøles og drikkes kald. Dersom du 
foretrekker søt te kan du bruke suketter etter eget ønske. 
 
Av juicen drikker du en kartong granateplejuice og en kartong druejuice hver dag. 
Når du har drukket grønn te/sort te/granateplejuice/druejuice er det viktig at du registrerer 
dette i skjemaet ” Skjema for registrering av produkter i forsøksperioden: multi-diett 
gruppe”. 
 
For dag 15/3-2007, og dag 2, 6/3-2007 vil dette se slik ut: 
 Merke 
navn 
Produkt Inntak Dag 1 Dag 2 Dag 3 
 Dato: 5/3 6/3  
Barilla Pastasaus med 
basilikum 
½ glass ×   
Dolmio Pastasaus extra 
hvitløk 
½ glass    
Dolmio Pastasaus classico ½ glass    
A
v 
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ss
e 
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 d
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Knorr Pastasaus med 
oregano og løk 
½ glass    
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Cadisco Tomatjuice ¼ 
kartong 
 ×  
ICA Tomater, hakket ½ 
kartong 
   
Twining
s 
Java grønn te 1 kopp × ×  
Twining
s 
Earl grey te 1 kopp × ×  
 Granateplejuice 330 mL × ×  
 Druejuice 330 mL × ×  
Dosett Kosttilskudd 1 Alle    
D
is
se
 p
ro
du
kt
en
e 
sk
al
 in
nt
as
 d
ag
lig
 
 Kosttilskudd 2 Alle    
 
Kosttilskudd 
 
Dose 1 (morgen) består av 3 × 1000 mg fiskeolje (Nycoplus omega-3), 2 × 40 mg soya 
(Natures`s sunshine Super soy extra), 1 ×100 μg selen (Solaray selen) og skal inntas på 
morgenen.  
Dose 2 (kveld) inneholder 2 × 1000 mg fiskeolje(Nycoplus omega-3), 3 × 40 mg soya 
(Natures`s sunshine Super soy extra), 1 ×100 μg selen (Solaray selen)  og skal inntas på 
kvelden. 
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Du har fått med Nycoplus omega-3, Natures`s sunshine Super soy extra og Solaray selen fra 
apoteket. Det står tydelig merket på boksene hvilke doser som skal tas av hvert enkelt 
preparat morgen og kveld. Ta kontakt med oss dersom du er i tvil! 
 
Det er ikke nødvendig å ta kosttilskuddene til måltidene, og de kan tas med drikke 
etter eget ønske.  
 
Når du har tatt en dose av kosttilskuddene er det viktig at du krysser av dette i skjemaet 
”Skjema for registrering av produkter i forsøksperioden: Multi-diett gruppe”. 
 For dag 1, 5/3-2007, og dag 2, 6/3-2007, vil dette se slik ut: 
 Merke 
navn 
Produkt Inntak Dag 1 Dag 2 Dag 3 
 Dato: 5/3 6/3  
Barilla Pastasaus med 
basilikum 
½ glass ×   
Dolmio Pastasaus extra 
hvitløk 
½ glass    
Dolmio Pastasaus classico ½ glass    
Knorr Pastasaus med 
oregano og løk 
½ glass    
A
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Cadisco Tomatjuice ¼ 
kartong 
 ×  
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ICA Tomater, hakket ½ 
kartong 
   
Twining
s 
Java grønn te 1 kopp × ×  
Twining
s 
Earl grey te 1 kopp × ×  
 Granateplejuice 330 mL × ×  
 Druejuice 330 mL × ×  
Dosett Kosttilskudd 1 Alle × ×  
D
is
se
 p
ro
du
kt
en
e 
sk
al
 in
nt
as
 d
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 Kosttilskudd 2 Alle × ×  
 
Du har fått utdelt nok produkter til 25 dager. Dette er fordi det for noen kan være 
vanskelig å få til nøyaktig 21 dager. Dersom du har produkter til over etter avsluttet 
forsøksperiode, trenger du ikke levere disse tilbake til oss. 
 
Skjemaet ”Skjema for registrering av produkter i forsøksperioden: Multi-diett 
gruppe” som du har fylt ut underveis, sendes til oss etter forsøksperioden i den 
frankerte konvolutten du har fått tilsendt. 
 
 
 
Lykke til! 
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Dersom du har spørsmål om undersøkelsen kan du når som helst kontakte oss. 
 
Lykke til!! 
 
Anette Karlsen, prosjektkoordinator, UiO  Tlf 22 85 15 24  
e-mail: anette.karlsen@medisin.uio 
 
Magnhild Kverneland, prosjektmedarbeider  Tlf 41 00 56 89  
e-mail: magnhild.kverneland@studmed.uio.no 
               
Guro Lindviksmoen, forskningssykepleier  Tlf 22 93 57 74 
e-mail:guro.lindviksmoen@radiumhospitalet.no 
 
Wolfgang Lilleby, behandlende lege   Tlf 22 93 40 00  
e-mail: wolfgang.lilleby@medisin.uio.no
Appendix 8 Skjema for registrering av daglig inntak for cocktailgruppen 
Skjema for registrering av produkter i forsøksperioden: multi-diett gruppe    ID nr:  
Skjemaet er på 4 sider (1 side for hver uke).  
For hver dag skal du velge en porsjon av tomatprodukt gitt i tabellen. Den mengden som tilsvarere en porsjon som du skal spise 
eller drikke er gitt under inntak (kolonne 4). Det du spiser daglig skal registreres i tabellene. 
Da det for mange kan være vanskelig å få til nøyaktig 21 dager, går skjemaene til og med 25 dager. 
Skjemaene sendes til oss i den frankerte konvolutten du har fått, etter forsøksperiodens slutt. 
 
Uke 1: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 1 Dag 2 Dag 3 Dag 4 Dag 5 Dag 6 Dag 7 
 Dat  o:       
 153 
Barilla Pastasaus med 
basilikum 
½ glass        
Dolmio Pastasaus extra 
hvitløk 
½ glass        
Dolmio Pastasaus classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ glass        
Cadisco Tomatjuice ¼ 
kartong 
       
A
v
 
d
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
k
a
n
 
d
u
 
v
e
l
g
e
 
e
n
 
p
o
r
s
j
o
n
 
d
a
g
l
i
g
 
ICA Tomater, hakket ½ 
kartong 
       
 
Twining
s 
Java grønn te 1 kopp        
Twining
s 
Earl grey te 1 kopp        
 Granateplejuice 330 mL        
 Druejuice 330 mL        
D
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
s
k
a
l
 
i
n
n
t
a
s
 
d
a
g
l
i
g
 
Dosett Kosttilskudd 1 Alle        
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 Kosttilskudd 2 Alle        
 
Uke 2: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 8 Dag 9 Dag 10 Dag 11 Dag 12 Dag 13 Dag 14 
 Dat  o:       
Barilla Pastasaus med 
basilikum 
½ glass        
Dolmio Pastasaus extra 
hvitløk 
½ glass        
Dolmio Pastasaus classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ glass        
Cadisco Tomatjuice ¼ 
kartong 
       
A
v
 
d
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
k
a
n
 
d
u
 
v
e
l
g
e
 
e
n
 
p
o
r
s
j
o
n
 
d
a
g
l
i
g
 
ICA Tomater, hakket ½ 
kartong 
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Twining
s 
Java grønn te 1 kopp        
Twining
s 
Earl grey te 1 kopp        
 Granateplejuice 330 mL        
 Druejuice 330 mL        
Dosett Kosttilskudd 1 Alle        
D
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
s
k
a
l
 
i
n
n
t
a
s
 
d
a
g
l
i
g
 
 Kosttilskudd 2 Alle        
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Uke 3: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 15 Dag 16 Dag 17 Dag 18 Dag 19 Dag 20 Dag 21 
 Dat  o:       
Barilla Pastasaus med 
basilikum 
½ glass        
Dolmio Pastasaus extra 
hvitløk 
½ glass        
Dolmio Pastasaus classico ½ glass        
Knorr Pastasaus med 
oregano og løk 
½ glass        
Cadisco Tomatjuice ¼ 
kartong 
       
A
v
 
d
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
k
a
n
 
d
u
 
v
e
l
g
e
 
e
n
 
p
o
r
s
j
o
n
 
d
a
g
l
i
g
 
ICA Tomater, hakket ½ 
kartong 
       
 
D
i
s
s
e
 
p
r
o
d
u
k
t
e
Twining
s 
Java grønn te 1 kopp        
 157 
Twining
s 
Earl grey te 1 kopp        
 Granateplejuice 330 mL        
 Druejuice 330 mL        
Dosett Kosttilskudd 1 Alle        
 Kosttilskudd 2 Alle        
 
Uke 4: 
Kryss av det du har spist eller drukket hver dag 
 Merke 
navn 
Produkt Inntak Dag 22 Dag 23 Dag 24 Dag 25
 Dato:     
Barilla Pastasaus med 
basilikum 
½ glass     
Dolmio Pastasaus extra 
hvitløk 
½ glass     
A
v
 
d
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
k
a
n
 
d
u
 
v
e
l
g
e
 
e
n
 
p
o
r
s
j
o
n
d
a
g
l
i
g
Dolmio Pastasaus classico ½ glass     
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Knorr Pastasaus med 
oregano og løk 
½ glass     
Cadisco Tomatjuice ¼ 
kartong 
    
ICA Tomater, hakket ½ 
kartong 
    
Twining
s 
Java grønn te 1 kopp     
Twining
s 
Earl grey te 1 kopp     
 Granateplejuice 330 mL     
 Druejuice 330 mL     
Dosett Kosttilskudd 1 Alle     
D
i
s
s
e
 
p
r
o
d
u
k
t
e
n
e
 
s
k
a
l
 
i
n
n
t
a
s
 
d
a
g
l
i
g
 
 Kosttilskudd 2 Alle     
 
 
Dersom du har spørsmål underveis, må du gjerne ta konatkt med oss. 
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Lykke til!! 
 
Anette Karlsen, prosjektkoordinator, UiO  Tlf 22 85 15 24  
e-mail: anette.karlsen@medisin.uio 
 
Magnhild Kverneland, prosjektmedarbeider  Tlf 41 00 56 89  
e-mail: magnhild.kverneland@studmed.uio.no 
               
Guro Lindviksmoen, forskningssykepleier  Tlf 22 93 57 74 
e-mail:guro.lindviksmoen@radiumhospitalet.no 
 
Wolfgang Lilleby, behandlende lege   Tlf 22 93 40 00  
e-mail: wolfgang.lilleby@medisin.uio.no 
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Appendix 9 Indexes results 
Appendix 9: Oxidative stress indexes as the sum of normalized values from the prostate cancer intervention study. Comparison of baseline values and changes during 
the intervention period: Endogenous index (GSH+Cysteine), Damage index (8OHdG+HEL+d-ROMs test+DHAA:TAA), Antioxidant index (Lycopene, TAA, mod FRAP) 
and combined index (DHAA:TAA + GGT + d-ROMs test – GSH – Cysteine). A p-value below 0.050 is considered statistical significant. Non-normally distributed 
parameter, presented as median (range). Mann-Whitney test was performed to compare the differences between the groups. 
Parameter Tomato groupa 
baseline 
Tomato groupa 
difference 
Control groupa 
baseline 
Control groupa 
difference 
Multidiet 
groupa 
baseline 
Multidiet 
groupa 
difference 
P (difference) 
tomato vs 
control 
P 
(difference) 
multidiet vs 
control 
Endogenous 
index 
n=8  
-0.2 (-1.1 – 1.1) 
n=8  
0.0 (-0.8 – 0.5) 
n=9 
0.1 (-0.9–0.9) 
n=9 
0.3 (-0.8 – 0.8) 
n=8 
-0.0 (-0.5 – 1.3) 
n=8 
-0.3 (-1.5 – 1.5) 
0.630 0.481 
Damage index n=7 
-0.1 (-0.8 – 0.8) 
n=7 
-0.1 (-0.8 – 0.6) 
n=8 
-0.1(-0.7– 0.8) 
n=8 
0.0 (-0.6 – 0.5) 
n=9 
0.1 (-0.7 – 0.6) 
n=9 
-0.0 (-0.8 – 0.7) 
0.699 0.700 
Antioxidant 
index 
n=7 
0.1 (-0.8 – 1.4) 
n=7 
-0.0 (-0.9 – 1.0) 
n=8 
-0.2 (-0.5 – 0.6) 
n=8 
-0.0 (-1.2 – 0.8) 
n=9 
-0.0 (-0.6 – 1.0) 
n=9 
0.2 (-1.0 – 0.6) 
0.817 0.773 
Combined index n = 5 
-0.3 (-0.9 – 1.0) 
n = 5 
-0.0 (-0.5 – 0.3) 
n = 8 
-0.1 (-0.7 – 0.6) 
n = 8 
-0.3 (-0.6 – 0.5) 
n = 8 
-0.1 (-1.0 – 0.8) 
n = 8 
0.0 (-0.7 – 0.7) 
0.661 0.529 
a Non-normally distributed parameter, presented as median (range). Mann-Whitney test was performed to compare the groups. 
